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ABSTRACT OF THE DISSERTATION

Regulatory Mechanisms of Uterine Artery Contractility:
Effect ofPregnancy
by
DaLiao Xiao

Doctor ofPhilosophy, Graduate Program in Pharmacology
Loma Linda University, June 2004
Dr. Lubo Zhang, Chairperson

Regulation of uterine blood flow during pregnancy is important not only for the
growth and survival ofthe fetus but also for cardiovascular well-being ofthe mother.
Pregnancy is associated with a significant decrease in uterine artery vascular tone and a
dramatic increase in uterine blood flow. Previous studies have been focused on

adaptation ofthe endothelium to pregnancy and indicated that increased NO

sythesis/release plays an important role in vasodilation ofthe uterine artery in pregnancy.
However, little is known about the adaptation of contractile mechanisms ofthe uterine
artery to pregnancy. The central hypothesis ofthe proposed studies is that extracellular

signal-regulated kinase(ERK)and protein kinase C(PKC)pathways interact in the

regulation of uterine artery contractility and play an important role in the adaptation of
uterine artery contractile mechanisms to pregnancy. To test this hypothesis, we propose a
series of experiments in the uterine arteries obtained from nonpregnant and near-term

(-140 Days)pregnant sheep. We found that ERK plays an important role in the

regulation of uterine artery contractility, and its effect is agonist-dependent. More
importantly, pregnancy selectively enhances the role ofERK in ai-adrenoceptormediated contractions and its effect in suppressing protein kinase C-mediated contraction

X

in the uterine artery. Our data indicate that ERK potentiates the thick filament regulatory
^I

0+

pathway by enhancing LC20 phosphorylation via increases in [Ca ], and Ca sensitivity
of LC20 phosphorylation. In contrast, ERK attenuates the thin filament regulatory
pathway, and suppresses contractions independent of changes in LC20 phosphorylation in
the uterine artery. We also found that pregnancy upregulates ai-adrenoceptor-mediated

Ca^"^ mobilization and LC20 phosphorylation. In contrast, pregnancy downregulates the
Ca^^ sensitivity of myofilaments, which is mediated by both thick and thin filament

pathways. ERK inhibitor, PD098059 significantly inhibited ERK44/42,MYPT1/Thr^^°
phosphorylation but not MYPTl/Thr®^^ and CPI-17/Thr^^. It suggests that ERK mediated
9+

Ca sensitivity is due to, at least, partly through inhibition of MLCP activity. On the

other hand, activation ofPKC by PDBu results increase in CPI-17/Thr phosphorylation
and contraction without changes in LC20 phosphorylation. These results imply that PKC9+

CPI-l7-mediated Ca sensitivity of contraction might be through thin filament pathway
in the uterine artery.
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CHAPTER ONE

General Introduction

Introduction

A. Physiological Changes of Uterine Artery during Pregnancy
Pregnancy is associated with physiological changes in the maternal cardiovascular
system that ensure normal fetal development. The dramatic alterations in arterial size

and function during pregnancy are unique to the uterine artery. As pregnancy

progresses, the uterine blood flow increases from 23 to >1,250 ml/min (80, 84). In
late pregnancy,the uterine arteries carry about 20% ofthe maternal cardiac output,
with approximately 80% ofthe uterine blood flow going to the placenta. Regulation
of uterine blood flow during pregnancy is important not only for the growth and
survival ofthe fetus but also for cardiovascular well-being ofthe mother. Several

factors account for the striking increase of uterine blood flow during pregnancy,
including growth of new vessels and remodeling ofexisting vessels in early
pregnancy, and decreased vascular tone in these vessels.

The structure ofthe uterine artery changes markedly during pregnancy to

accommodate the substantial increase in uterine blood flow. Uterine artery diameter
markedly increased during pregnancy in the human(5, 80), pig (36)and sheep (30).
The diameter ofthe uterine artery increases, as measured in situ, from 2.8 mm in
nonpregnant ewes to 5.0 mm or greater during the late pregnancy (30). The increase

in diameter ofthe uterine artery with pregnancy is not merely the result of passive

dilation, since wall thickness is unchanged (35). This finding suggests that there is
active growth ofthe uterine arterial wall. Griendling at al.(35)suggested that this

1

arterial growth is accomplished by a 2.5-fold increase in smooth muscle mass per unit
length of vessel, despite no change in wall thickness. During pregnancy the number
of cells per unit area and the diameter ofthe cells are unchanged; however, the
numbers of nuclei per unit area decrease in the uterine artery (5). This could be

explained in the case in which cells were elongated, thus reducing the probability of
sectioning through the nucleus. Growth in cell length could explain the increase in
uterine arterial diameter seen in pregnancy. Although it does not exclude a

component of hyperplasia, it does favor hypertrophy as a major factor in accounting

for vessel growth. Such hypertrophy might be more readily reversible after
pregnancy than hyperplasia and may account for the rapid loss ofthose characteristics

acquired during pregnancy (5). The biochemical changes in the uterine artery during
pregnancy have also been observed. It has been found that there was a significant
increase in protein contents ofthe uterine arteries from pregnant ewes than those from

nonpregnant ewes but no difference ih the frdbtibiial cellular composition of the
muscularis (5). The increased protein content resulted in an increase in contractile
protein contents and the total amount of myosin light chain phosphorylated in
response to stimulation with phenylephrine. Thus significant biochemical alterations
occur that can, in part, explain on a cellular level the observed increases in stress of

uterine arterial smooth muscle associated with pregnancy.

Growth of new vessels as well as remodeling of existing vessels during early
pregnancy contributes to the increased uterine blood flow. However,the fact that the

period of greatest increase in uterine blood flow occurs after the completion of new
vessel growth indicates that, in addition to those structural changes,functional

alterations and maintenance of vasodilation in existing or newly developed vessels

are crucial. Normal pregnancy is associated with reductions in total vascular
resistance and arterial pressure possible due to enhanced endothelium-dependent
vascular relaxation and decreased vascular reactivity to vasoconstrictor agonists.
Previous studies have been focused on adaptation ofthe endothelium to pregnancy

and demonstrated that increased nitride oxide(NO)synthesis/release plays an
important role in the maintenance of vasodilation in the uterine artery in pregnancy
(9,65, 74, 89,98, 100, 101,102). However, little is known about the adaptation of

contractile mechanisms of uterine artery smooth muscle to pregnancy. Sympathetic
activation of ai-adrenoceptors plays an important role in moment-to-moment

regulation of vascular contractility. Although pregnancy decreases uterine artery
vascular tone, it paradoxically increases acute contractile response ofthe uterine

artery to nonsynaptic ai-adrenergic stimulation (4, 5,18,19, 77), due probably in part

to the transient and reversible sympathetic detiefvation of uterine artery during
pregnancy(56,73). The sympathetic neurotransmitter norepinephrine, acting

postsynaptically at the smooth muscle ai-adrenergic receptors, is a principal

determinant of vascular contractility ofthe uterine artery. Alphai-adrenergic
receptors play a particularly important role in control of blood pressure via induction
of vascular smooth muscle contraction. Alphai-adrenergic receptor signaling

mechanism generally involve coupling to the G proteins; these G proteins activate

phospholipase C,leading to increased hydrolysis of phospharidylinositol 4,5bisphosphate to inositol 1,4,5-triphosphate and 1,2-diacylglycerol, which increase
^I

intracellular Ca concentration and activate protein kinase C(PKC),respectively.

Although this predominant view of ai-receptor signaling provides substantial insight
into ai-receptor-mediated respdnses in various cells, there are clear indications that

these mechanisms may not explain all aspects of ai-receptor signaling. Recent
evidence demonstrates that ai-receptor-stimulated mitogenic responses in myocj^es
may be due to activation oftyrosine protein kinases and MAP kinases, suggesting that
ai-adrenergic receptors may share common signal pathways with tyrosine kinase
receptors in the stimulation of mitogenesis. Moreover,recent studies have
demonstrated a direct relationship between MAP kinase activation and smooth

muscle contraction(3, 20,49). However, signaling pathways utilized by ai-receptors
in promoting mitogenic effects, such as grov^-related gene expression and DNA

synthesis, and the cause-and-effects relationship between MAP kinase activation and
smooth muscle contraction are still not fully understood. On the other hand, it has

been demonstrated that PKC is also important in the regulation of basal vascular tone

and arterial caliber, which is a major determinant of blood flow (7, 16, 59, 67, 78).
Although a growing body of evidence suggests a role for PKC in smooth muscle

contraction, little information is available on the changes in vascular PKC activity
and the regulation ofPKC activity during pregnancy. It has reported that PKC
activity(64)and PKC-mediated contractile pathway(46)in vascular smooth muscle
is reduced during pregnancy. The results suggest that one possible mechanism ofthe

pregnancy-associated changes in vascular reactivity may involve changes in the
amount and/or activity ofthe PKC isoforms and the down stream signal pathways.
B. Hormonal regulation of the uterine artery contractility

Changes in uterine blood flow throughout pregnancy appear to be due to steroid

inducded alterations in uterine arterial tone and contractility. In pregnancy, tone is
markedly depressed as estrogen concentrations rise, and the vessel is distended and

flaccid. Estrogens are vasoactive substances, influencing the vascular wall mainly
through gene modulation by the estrogen receptor(s), identified on endothelial and

vascular smooth-muscle cells. A direct effect of estrogens was also postulated, which
may be the result of post-translational modification of enzymes. Whereas gens

modulation typically results in long-term effects, direct steroid actions can rapidly
influence vascular function. Estrogens respectively augment and restore

endothelium-dependent vasodilation in atherosclerotic blood vessels by increasing
local NO concentraction. This is caused either by enhancing endothelial NOS
activity or by inhibiting NO degradation, as estrogens are potent antioxidants.
Besides their influences on the NO system, estrogens stimulate the activity ofPGI2
and EDHF while attenuating vasoconstrictor effects mediated by TXA2 and ET-1.

Direct effects of estrogens on prolififatioh ahd bSigration of vascular smooth-muscle
cells and calcium channel blocker-like actions have been docemented (27). The
progressive decrease in uterine arterial tone during gestation seems to result from the
metabolism of placental estrogens to vasoactive catechol forms(27, 28). It has been
demonstrated that peroxidases catalyze the conversion of estrogens to catechol

estrogens. Extremely high concentrations of estrogens and peroxidase are detected in
uterine lymphatic fluid during pregnancy(28). These lymphatics are in close contact
with the uterine arterial vasculature and thus may serve to transport catechol
estrogens. The catechol estrogens specifically inhibit calcium uptake through the
potential-sensitive calcium channels and terminate the PKC-maintained tone ofthe

uterine arteries. In conjunction with the decreased calcium uptake through uterine

arterial potential sensitive calcium channel, cellular PKC activity also progressively
decreases throughout gestation in pigs (25). It is suggested that the decreasing PKC
activity of uterine arterial smooth muscle may be a direct result ofthe catechol

estrogen-induced inhibition of calcium uptake through the potential-sensitive calcium
channel. Progesterone, in contrast to estrogen, augments the responsiveness of

vascular smooth muscle to norepinephrine. During the estrous cycle of ewes,the

higher the estrogenrprogesterone ratio in systemic blood, the greater is the quantity of
blood flowing through the uterine vascular bed. After the initial increase in blood

flow to the uterus dining early pregnancy, changes in the estrogenrprogesterone ratio
in fetal and maternal fluids appear to be unrelated to changes in uterine blood flow.
This lack of association between the estrogenrprogesterone ratio and uterine blood

flow may result from a progressive reduction in number of adrenergic nerces

observed in the uterus throughout piclhahGy. if one accepts that the
estrogenrprogesterone ratio controls uterine blood flow throgh alterations in the

function of periaterial adrenergic nerves, the impaired function ofthe nerves during
mid and late gestation may preclude the effects ofthese steroids.
C. The role ofPKC in the regulation of smooth muscle contraction

The role ofPKC in the regulation of many biological functions is widely accepted

(40). There are at least 11 PKC isoenzymes divided into three major groupsr 1)
classical group A PKCsr a, pi, pll, and y; 2)novel group B PKCsr 5, s, p, and 0; 3)
atypical group C PKCs:

i, and A,(49, 96). The molecular structures ofPKC

isozymes are shown in Fig. 1. The multiplicity ofPKC isozymes creates a challenge

in determining the involvement of each in specific signaling events. Group A and
group B PKCs translocate, in general, from the Cytosol to membranous sites upon
activation with diacylglycerol(DAG)and certain phorbol esters. However,they
94-

94-

differ markedly in their sensitivity to Ca . Group A PKCs are Ca -dependent via

their C2 domains and are activated by phosphatidylserine (PS),DAG and phorbol
94-

esters through their cysteine-rich C1 domains. Group B PKCs are Ca independent
but are also regulated by PS,DAG and phorbol esters. Group C PKCs are neither
91

Ca -dependent nor require PS,DAG or phorbol esters for their activation(75, 83).

All three PKC groups contain a pseudo-substrate or autoinhibitory domain that binds
to the substrate-binding site in the catalytic domain preventing their activation in the
absence of cofactors or activators. PKC activation is also regulated by

phosphorylation, and both PKC kinase(s) and PKC autophosphorylation are required
for full activity. Phosphorylation also regulates PKC subcellular localization and

down-regulation. The a,(5,5, s, arid % isObttiZyriilk ofPKC have been detected in
vascular smooth muscle (96). Although not all ofthese appear to be in all vascular
smooth muscle tissues, our preliminary data suggested that all ofthese isoenzymes of
PKC were present in the uterine artery. The involvement ofPKC activation in

Fig. 1. PKC kinase family members and their structure
DAG,

phorbol ester Calcium

binding

ATP

bin^ng binding

Classical PKCs

Kinase

(a, pi, pll,y)
Novel PKCs

(8,s, ri, 0)
Atypical PKCs

la—C1

C1

Kinase
Kinase

Schematic representaion ofPKC kinase family members and their structure,
CR,cysteine rich-lipid binding domain in Cl; PS,pseudosubstrate;
C2,calcium binding domain; C3,ATP binding domain.

smooth muscle contraction has been well demonstrated from the studies showing that

phorbol esters, known to activate PKC,induce slow sustained contractions in many
types of vascular smooth muscle(44, 75, 88). Whether and to what extent PKC
isoenzymes expression and activities in uterine artery smooth muscle adapt to
pregnancy is unknown.
D. The role of ERK in the regulation of smooth muscle contraction

Extracellular signal-regulated kinases(ERK1/2) are involved in the regulation of

essential cellular processes, including gene expression and cell proliferation (11, 86).
Recent studies have demonstrated that ERK plays a role in the regulation of smooth
muscle contraction (3, 20,31, 32,47, 97). Different signaling transduction
mechanisms have been reported in the ERK-mediated regulation of smooth muscle

contractions. In vascular smooth muscle, ERKl/2 aetivation in response to

emgiotensin(ANGII),thrombin, or ATP appears to involve both Ca^^ and PKCdependent mechanisms(2,10,12). Other studies have demonstrated that Ca^"^independent contractions are dramatically reduced with the MEK inhibitor
PD098059,in contrast to the Ca -dependent component ofthe agonists-evoked

contractions that are not affected by ERK(20,23). D'Angelo et al.(17)reported that
pretreating carotid arterial strips for 1 h with the MEK inhibitor PD098059 attenuated

ET-1-stimulated isometric force and the decrease in the rate of force development
caused by PD-098059 was associated with a reduction in myosin light chain(LC20)

phosphorylation. Pregnancy is associated with a growth of uterine vasculature and a
dramatic increase in uterine artery blood flow. It has been shown reeently that the
pregnancy-induced increase in uterine artery endothelial vasodilator production is

mediated in part by a marked alteration in signaling pathway including activation of

the ERK pathway(8,21). It is unknown whether ERK plays a role in the regulation of
uterine artery contractility, and more importantly, whether pregnancy affects the
potential role ofERK in the uterine artery.

E. Interaction between PKC and ERK in the regulation of smooth muscle
contraction.

Regulation and activation ofPKC and ERK are interrelated in vascular smooth
muscle. Adrenergic stimulation of vascular smooth muscle induces cellular

redistribution of both PKC and ERK(50, 51, 52). Studies have shovm a transient,
^I

Ca independent,PKC-dependent redistribution of cytosolic ERK to the plasma
membrane before cell contraction, followed by a second redistribution away from the
plasmalemma to the contractile filaments during cell contraction. Further studies

revealed that the initial association ofERK with the plasmalemma occurred in a

tyrosine phosphorylation-independeht ntidhhetj Whereas the delayed redistribution of
ERK,co-localizing with caldesmon, occurred in a tyrosine phosphorylationdependent marmer(49). These observations suggest a role for ERK as a link between
membrane-bound PKC and caldesmon during cell contraction (Fig. 2).
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It has been proposed in several studies that ERK is a downstream signal ofPKC
in vascular smooth muscle(14,48, 52). It has also been demonstrated that different
agents, which produce contractions of smooth muscle, activate ERK at the same time

(20,\31, 47). Although it has been suggested that PKC may be an upstream signal of
ERK in agonist-stimulated contractions of vascular smooth muscle, several studies
I

failed to see the inhibitory effect ofPD-098059 on PDBu-induced contractions(1, 34,
69), suggesting that an altemative pathway may be involved. The finding that the
PDBu-induced contraction was significantly attenuated in rat thoracic aorta during
pregnancy (46), suggesting that the role ofPKC in the regulation of vascular tone is
down-regulated during pregnancy. However,the cellular and molecular mechanisms

are unknown. One ofthe major goals ofthis project is to explore the
cellular/molecular mechanisms underlying ERK suppressing PKC-mediated

contraction during pregnancy, and hdw they hffeet uterine vascular resistance and
regulate uterine blood flow in pregnant sheep.
F. Contractile mechanisms in vascular smooth muscle

Vascular smooth muscle contraction is regulated predominantly by
phosphorylation and dephosphorylation ofthe 20-kD light chain of myosin(LC20)

(38,40,45, 81). Phosphorylation of LC20 is affected primarily by an increase in the

intraCellular Ca^"^ concentration ([Ca^"^]i). An increase in [Ca^"^]i results in the
activation of myosin light chain kinase(MLCK), which catalyzes phosphorylation of
LC20. Phosphorylation of LC20 results in actin activation of myosin ATPase

activity, the development offorce, and contraction ofthe muscle. Dephosphorylation

12

in LC20 phosphorylation levels, perhaps by thin filament-associated signaling

pathway(6,71). Taken together, smooth muscle contraction is regulated by thick
and thin filament regulatory pathways. Thick filament regulation is mediated by

Ca^'^-dependent mechanisms that lead to activation of MLCK and LC20

phosphorylation and by Ca^"^-independent mechanisms that involve inactivation of
MLCP and a decrease in LC20 dephosphorylation. On the other heind, thin filament

signaling transduction pathway is regulated throtigh both Ca^"^- and LG20
phosphorylation-independent mechanisms. An outline ofsome ofthe mechanisms

that may regulate the thick and thin filaments in smooth muscle is shown in Fig. 3.
The biochemical and physiological adaptations ofthese cascades that affect uterine

arterial smooth muscle contractility during pregnancy are undefined.
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G. The role of MLCP in the regulation of smooth inuscle contraction
A key event in agonist-induced Ca sensitization is G protein-dependent
inhibition of MLCP (55). MLCP consists ofthree subunits: a 110 to 130 kDa

regulatory subunit(MYPTl),a ~37 kDa catalytic subunit(PP-IC), and a 20 kDa

subunit of unknown function (39). It has been reported that inhibition of MLCP is, at
least, regulated by following three independent mechanisms(Fig. 4). 1)

Phosphorylation ofthe MYPTl leads to inhibition ofthe phosphatase (41). This may
occur via activation of Rho-associated kinase(ROK)(53), a kinase that is activated

by the small GTPase RhoA. 2)The second messenger arachidonic acid inhibits
MLCP activity by dissociation ofthe holoenzyme, as well as activation ofPKC and
Rho kinase (33). 3)Activation ofPKC leads to inhibition of MLCP (68). This may

be mediated by an endogenous, smooth muscle-specific phosphopeptide, CPI-17,

which becomes a very potent inhibitbf ofPP^^ld tipon phosphorylation by PKC(62).
Phosphorylation of MYPTl by ROK leads to inhibition of MLCP. Other substrates
of ROK include CPI-17 and calponin. However,there are concerns as to the access
of ROK to its substrate MYPTl because both Rho and ROK have to be recruited

from a cytosolic pool to the cell membrane for activation. Perhaps, a kinase, such as
ZIP kinase or ERK,could be a link between activated ROK and MYPTl, which leads
^1

to a Ca independent increase in force. Recent studies from Morgan's laboratory

(87)have provided evidence for another mechanism for Ca^"^ sensitization. Their data
show that there is an agonist-specific translocation of MLCP to smooth muscle cell
membrane. PGF2a stimulation ofsmooth muscle cells results in phosphorylation of
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MYPT at

and a translocation of MLCP from cytosol to cell membrane. The

catalytic and targeting,subunits ofthe MLCP are dissociated from each other in an

agonist-specific manner and that the dissociation is accompanied by a slower rate of
myosin phosphorylation. The phosphorylation and membrane translocation ofthe
MLCP targeting subunit are inhibited with a ROK inhibitor. Translocation ofPKC,

ERK,calponin, and Rho A have all been reported, but how these proteins interact

with MLCP and lead to inhibition of MLCP activity and to produce a Ca^^
independent contractions remain to be determined in uterine arteries.

At least two phosphorylation sites of MYPT1 have been identified at Thr^^^ and

Thr®^"(91). Previous reports have shown that phosphorylation of MYPTl/Thr^^®
through the RhoA/ROK pathway has been detected in a variety cells, including

smooth muscle (43,81,94). On the other hand, MYPTl/Thr^®® is constitutively
phosphorylated, by kinases other than Rho-kinase, and does not respond to agonists

(54, 76, 91). This implies that thefS i§ no dgoftiit mediated G-protein-coupled

signaling pathway leading to Thr^^^ phosphorylation in the smooth muscle. In

contrast to Thr^^^, MYPTl/Thr^^® is significantly phosphorylated in response to
agonist. These findings suggest an exciting hypothesis that the different
phosphorylation sites may regulate MLCP activities differently at basal and agonist-

stimulated states. MYPTl/Thr^^" is not an inhibitory site in vitro (26), but its
phosphorylation state could affect localization of MLCP and its catalytic subunit on

myosin (95), and thereby, in conjunction with Thr®'^ phosphorylation, may be

responsible for Ca^^-sensitizing inhibition of MLCP when Thr^^^ is constitutively
phosphorylated. It remains to be determined whether the difficulty in detecting
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phosphorylation of MYPTl/Thr^^^ reflects its rapid dephosphorylation or operation
of another RhoA/ROK-mediated mechanism that doCs not require Thr^^®
phosphorylation or is targeted to a different inhibitory residue not detected by the

Thr^^^-specific antibody.
Recent reports have indicated that CPI-17 plays a very important role in the G-

protein- and PKC-mediated inhibition of MLCP and Ca^^ sensitization. CPI-17 was

initially recognized as a PKC substrate and phosphorylated at the site of Thr^^ by
PKC(24)and it has been shown that Rho Kinase does also phosphoryalte CPI-17 in

vitro (57). Thus, both PKC and ROK signaling pathways may contribute to
regulation of MLCP activity through an increase in CPI-17 phosphorylation (54,76,

79). Protein kinases other than PKC can also phosphorylate the inhibitory (Thr^^) site
of CPI-17: ZIP-like kinase,PKN,integrin-linked kinase,PAK,and, most importantly,
ROK(91). It remains to be shown which ofthese kinases, particularly ROK,is

spatially and kinetically appropriate fdr phOsphbr^lating CPI-17.
H. Thin filament regulation of smooth muscle contraction and the major thin
filament-associated proteins

Thin filaments are defined as those filaments 6-8 nm in diameter and composed of
filamentous actin. The thin filament signal transduction pathway is regulated through

both Ca^"^ independent and LC20 phosphorylation independent mechanisms. If Ca^^
sensitization were to be explained solely by inhibition of MLCP or activation of
MLCK,sustained tension levels should always be paralleled by sustained LC20

phosphorylation levels, even if Ca^^ level falls. However,it is clear that during
agonist-induced contractions of vascular smooth muscle, LC20 phosphorylation
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levels do not parallel tension levels(22). This dissociation of LC20 phosphorylation
levels(myosin or thick filament regulation) and tension levels has been used as
evidence for the existence ofthin filament regulation. In addition, there is also

considerable direct evidence pointing to thin filament regulation in smooth muscle.
Evidence includes: 1)the fact that crossbridge cycling rates can vary without

detectable changes in LC20 phosphorylation (13, 37); and, most importantly, 2)the
fact that contraction can occur in the absence of changes in LC20 phosphorylation
(70). Thin filament regulatory proteins include caldesmon and calponin.
Caldesmon Recent studies on the smooth muscle actin-binding protein, caldesmon

(CaD), have strongly suggested an important, and physiologically relevant, role for
this protein in thin filament regulation. CaD is a thin filament-associated, actin,
tropomyosin, myosin and calmodulin(CaM)binding protein. Its properties have
been reviewed previously(40, 71). The molecular structure of CaD is shown in Fig.

5). Carboxy terminal domains are teSpOhsiblS for actin-binding and inhibition of
myosin ATPase activity. Either binding of CaM or phosphorylation of sites in Cterminal half ofthe molecule can reverse the myosin inhibition. The N-terminal half
ofthe molecule has been shown to bind myosin. CaD can acts as a cross-linker of
actin and myosin. The consistency between the peptide studies with GS17C and the

antisense studies strongly suggests that CaD plays a physiologically important role in

suppressing smooth muscle tone. Studies have suggested two possible mechanisms

by which inhibitory actions of CaD can be reversed: by the binding of Ca^VCaM and
by phosphorylation (71). It is known to be phosphorylated in vitro by a number of

protein kinases including CaMKII,casein kinase II, PKA,cdc2 kinase, ERK,and
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PKC. In vitro experiments have shown that phosphorylation of CaD by PKC or PAK

can reverse the inhibitory activity of CaD on myosin ATPase activity and can also
decrease the actin binding affinity of CaD. The function of CaD and the importance

of CaD phosphorylation at ERK sites are controversial issues. Childs et al.(15)
reported a significant effect ofERK phosphorylation on actin co-sedimentation of

CaD. In contrast, Krymsky et al.(58)have shown that ERK phosphorylation of
gizzaed CaD did not reverse its effects on myosin ATPase. Li et al.(63) have
recently shown that ERK phosphorylation at both S759 and S789 of a C-terminal

fragments actin binding. Similar results were presented by Marston et al.(66). The
role ofPKC and ERK in phosphorylation of CaD and its role in the regulation of
contraction in the uterine artery are unknown.

Calponin

Calponin(CaP)is another actin-binding protein that inhibits myosin

ATPase activity. CaP has three isoforms that are separate gene products: 1)a smooth

muscle-specific basic CaP, hi,2)a hiiitral CaP, h2,that has a very high sequence
homology with hi CaP but is less basic and is localized primarily in cardiac muscle,
and 3)acidic variant, which is not tissue specific, identified from rat brain and

fibroblasts. Regarding molecular structure of CaP,the CaP homology(CH)domain,
which has very high homology across isoforms, is followed by a variable region that

contains an actin binding region with homology to troponin 1(Tnl), referred to as the
Tnl-like sequence. This is followed by three C-terminal repeats that are also involved

in actin binding. CaP activity is regulated by phosphorylation by PKC or CaMKll,

both of which reverse CaP's inhibitory activity. The major phosphorylation site in
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vitro was identified as either Serl75(99)or Thrl84(72). It was also identified that
the CH domain of CaP is ERK binding domain(60).
The role of CaP in the regulation ofsmooth muscle contraction is controversial.
Two mechanisms have been proposed for its function. On one hand, it has been
suggested that CaP may directly inhibit actin-activated Mg-ATPase activity of
myosin. On the other hand, it has also been proposed that CaP may facilitate agonistinduced signal transduction (71). This hypothesis is based on the observations that, in
ferret vascular smooth muscle, in the early time points after agonist activation, ERK
and PKC co-immunoprecipitate and co-translocate with CaP to the vicinity ofthe
plasmalemma and the N-terminal'CH domain' of CaP binds ERK, while the C-

terminal half of CaP binds the regulatory domain ofPKC and facilitates the activation

ofPKC in vitro (61). Based on these results, these investigators have speculated that
CaP may function as an adaptor protein connecting the PKC cascade to the ERK
cascade. After docking and being activated at the cell surface, ERK redistributes to

the contractile filaments, phosphorylates CaD,and triggers contractions.

Aim of this project

The aim ofthe present project was to examine the main hypothesis that

regulatory meehanisms of ERK/PKC pathways in governing uterine artery

contractility are altered during pregnancy. To test this hypothesis, we propose a

series of experiments in uterine arteries from nonpregnant and near-term(~140 days)
pregnant sheep. Our specific aims are: 1)To test the hypothesis that pregnancy selectively
enhances the role ofERK in the regulation of ai-adrenoceptor-induced contractions and
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its effect in suppressing PKC-mediated contraction in the uterine artery; 2)To test the
hypothesis that ERK regulates smooth muscle contractility through both thick and thin
filament regulatory pathways in the uterine artery; 3)To test the hypothesis that

pregnancy up-regulates the thick filament regulatory pathway and down-regulates the
thin filament regulatory pathway in the uterine artery; 4)To test the hypothesis that ERK
inhibits myosin phosphatase activity by phosphorylating its regulatory/targeting subunit
MYPTl,and CPI-17 which contributes to pregnancy-mediated up-regulation ofthe thick
filament regulatory pathway in the uterine artery.

Significance

The proposed studies are ofimportance from both basic science and clinical
perspectives. From the basic science point of view,the proposed studies of both thick

and thin filament regulatory pathways are especially powerful means of evaluating

mechanisms governing uterine artery cbtttfactilityi ihd thereby enhance our basic
understanding of uterine vasculature adaptation to pregnancy. They will provide exciting
novel information from several standpoints. They will be the first to examine PKC
isoenzymes expression and their functions in the uterine artery, and examine the effect of
pregnancy. They will be the first to offer assessment ofthe dynamic interactions ofERK

and PKC in the uterine artery, and to test the novel hypothesis that ERK is an upstream
signal in suppressing PKC activity. They will be the first concerted effort to understand
the mechanisms imderlying both thick and thin filament regulatory pathways in the
uterine artery. Most importantly,these novel assessments will extend to pregnant uterine

artery in which such studies are extremely rare. Not only are these studies important to
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understand basic mechanisms rmderlying adaptation of uterine artery contractile

machinery to pregnancy, but they will also offer novel information in understanding
signaling mechanisms for vascular contraction in general.

The proposed studies are relevant to the mechanisms involved in adjusting
uteroplacental circulation to pregnancy. Given the importance of uterine blood flow in
fetal development and maternal health, failure to make these adjustments is likely to

contribute to many fetal abnormalities, including intrauterine growth restriction, as well
as maternal cardiovascular disorders. The proposed studies will help provide a

mechanistic basis for this functional adaptation, and thereby improve our vmderstanding
of problems associated with the maladaptation and abnormal pregnancy and permit us to
address them in a more meaningful way.
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Abstract

The present study investigated the potential role of extracellular signal-regulated

kinase(ERK)in uterine artery contraction, and tested the hypothesis that pregnancy upregulated ERK-mediated function in the uterine artery. Isometric tension in response to
phenylephrine (PE), serotonin(5-HT),PDBu and KCl was measured in the ring
preparation of uterine arteries obtained from nonpregnant and near-term (140 d gestation)
pregnant sheep. Inhibiting ERK activation with PD-98059 did not change the KCI-

evoked contraction but significantly inhibited the contraction to 5-HT in both
nonpregnant and pregnant uterine arteries. PD-98059 did not affect PE-induced
contraction in nonpregnant but significantly decreased it in pregnant uterine arteries. In
accordance,PE stimulated activation ofERK in pregnant uterine arteries, which was
blocked by PD-98059. PD-98059-mediated inhibition ofthe PE-induced contraction was

associated with a decrease in both intracellular Ca^"^ Concentration and Ca^"^ sensitivity of
contractile proteins in pregnant uterine arteries. PDBu-mediated contraction was
significantly less in pregnant than nonpregnant uterine arteries. PD-98059 had no effect
on PDBu-induced contraction in nonpregnant but significantly increased it in pregnant
uterine arteries. In addition, PD-98059 significantly enhanced PDBu-stimulated protein

kinase C activity. The results indicate that ERK plays an important role in the regulation

of uterine artery contractility, and its effect is agonist-dependent. More importantly,
pregnancy selectively enhances the role ofERK in ai-adrenoceptor-mediated

contractions and its effect in suppressing protein kinase C-mediated contraction in the
uterine artery.
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Introduction

Extracellular signal-regulated kinase(ERK)has been proposed to regulate smooth
1 or

muscle contraction. Activation ofERK is dependent on a dual-phosphorylation on Tyr

and Thr^^' by mitogen-activated/extracellular-regulated kinase kinase or MEK (5,6,34).
It has been demonstrated in many studies that different agents, which produce
contractions of smooth muscle activate ERK at the same time (4,9,10,13,14,23,39).
However, conflicting results were obtained regarding a role for ERK in smooth muscle

contractile regulation. A cause-and-effect relationship between ERK activation and ai-

adrenoceptor-mediated contraction was demonstrated in ferret aorta(10). In addition,

addition of activated ERK to permeabilized airway smooth muscle strips resulted in a
•

9+

contraction by increasing Ca sensitivity of contractile proteins (13). In contrast, studies
with permeabilized rabbit vascular smooth muscle preparations showed no effect ofERK

on Ca^"^ sensitivity (32). Furthermore, ih §Mhe cdfbtid artery, inhibition of MEK with
PD-98059 had no effect on histamine and phorbol 12,13-dibutyrate (PDBu)-mediated
contractions (15).

It is unknown whether ERK plays a role in the regulation of uterine artery
contractility, and more importantly, whether pregnancy effects the potential role ofERK

in the uterine artery. Pregnancy is associated with a growth of uterine vasculature and a
dramatic increase in uterine artery blood flow. It has been shown recently that the
pregnancy-induced increase in uterine artery endothelial vasodilator production is
mediated in part by a marked alteration in signaling pathway including activation ofthe
ERK pathway (7). In the present study, we tested the hypothesis that the ERK pathway
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played an important role in the regulation of uterine artery contractility in an agonistdependent maimer. Furthermore, we tested the hypothesis that pregnancy selectively
enhanced the role ofERK in ai-adrenoceptor-induced contractions and its effect in

suppressing proteiri kinase C(PKC)-mediated contraction in the uterine artery.
Specifically, we examined the effect ofPD-98059(a selective MEK inhibitor) on
phenylephrine-, 5-HT-,PDBu- and KCl-induced contractions in both pregnant and
nonpregnant uterine arteries. ERK activity was measured using a phosphospecific ERK

1/2 antibody. We also examined the role ofintracellular Ca^"^ concentration ([Ca^^Jd and
Ca^"^ sensitivity in the ERK-mediated response, and tested the hypothesis that both the
Ca dependent and independent components were involved in the ERK pathway in the
uterine artery.
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Methods

Tissue preparation' Nonpregnant and pregnant(-140 days gestation) sheep were
anesthetized with thiamylal(10 mg/kg)administered via the external left jugular vein.
The ewes were then intubated and anesthesia was maintained on 1.5% to 2.0% halothane

in oxygen throughout surgery. An incision in the abdomen was made and the uterus

exposed. The uterine arteries were isolated and removed without stretching and placed
into a modified Krebs solution

(pH 7.4) ofthe following composition (in mM): 115.21 NaCl,4.7 KCl, 1.80 CaCli, 1.16
MgS04, 1.18 KH2PO4,22.14 NaHCOs,and 7.88 dextrose. EDTA (0.03 mM)was added
to suppress oxidation of amines. The Krebs solution was oxygenated with a mixture of
oxygen-carbon dioxide (95:5%). After removal ofthe tissues, animals were killed with
T-61 (euthanasia solution, Hoechst-Roussel, Somervile, NJ). All procedures and

protocols used in the present study were approved by the Animal Research Committee of
Loma Linda University and followed the guidelines put forward in the National Institutes
of Health Guide for the Care and Use of Laboratory Animals.

Contraction studies. The third (nonpregnant) and fourth (pregnant) branches of
the main uterine arteries were separated ftom the surrounding tissue, and special care was
taken to avoid touching the luminal surface. The arteries were cut into 2-mm ring

segments. In some rings the endothelium was removed by gentle rotation ofthe arterial

rings on an approximately sized, rough-surfaced blunt hypodermic needle as described
previously (20). Contractile responses were quantified in Krebs' solution in tissue baths
at 37 °C as described previously(20). Isometric tensions were measured. After 60 min
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of equilibration in the tissue bath, each ring was stretched to the optimal resting tension

(1 g) as determined by the tension developed in response to potassium chloride(120 mM)
added at each stretch level. Concentration-response curves were obtained by cumulative

addition ofthe agonist in approximate one-halflog increments. EC50 values for the

agonist in each experiment were taken as the molar concentration at which the
contraction-response curve intersected 50% ofthe maximum response, and were
expressed as pD2(-logECso) values. All responses are normalized to the maximal high
KCl(120 mM)contraction.

Immunoblotting. Arterial rings were equilibrated in the tissue bath and the

optimal tension was obtained as described above. The tissues were then incubated for 30
min with PD-98059(30 pM)or vehicle alone in the organ bath(37 °C). After

incubation, they were stimulated with phenylephrine(3 pM). The reaction was stopped
by snap-freezing the tissues in liquid nitrogen and stored at -80 °C imtil used. Frozen

samples were homogenized in a lysis buffer containing 150 mM NaCl,50 mM Tris HCl,
10 mM EDTA,0.1% Tween 20,0.1% P-mercaptoethanol, 0.1 mM phenylmethylsulfonyl
fluoride, 5 pg/ml leupeptin, and 5 pg/ml aprotinin, pH 7.4. Sample homogenates were

then centrifuged at 4 °C for 5 min at 6,000 g and the supematants were collected. Protein
was quantified in the supernatant using protein assay kit from Bio-Rad. Samples with

equal protein were loaded on 10% polyacrylamide gel with 0.1% sodium dodecyl sulfate
(SDS)and were separated by electrophoresis at 100 V for 2 h. Proteins were then
transferred on to immobilon P membrane at 30 V for 50 min at room temperature using a

semidry blotter (Bio-Rad). Nonspecific binding sites in the membranes were blocked by

an ovemight incubation at 4 °C in a Tris-buffered saline solution(TBS)containing 5%
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dry milk. The membranes were washed in TBS(3x 15 min)and then incubated with

rabbit phospho-p44/42 MAP kinase (Tyr-202/tyr-204) antibody (at 1:1,000 dilution; New
England Biolabs, Beverly, MA). Total p44/42 MAP kinase(ERK-1/2) was determined
using anti-ERK-1/2 antibody(New England Biolabs, Beverly, MA). Membranes were
washed using TBS and then incubated with horseradish peroxidase-conjugated goat antirabbit secondary antibody (1:2,000) obtained from Amersham (Arlington Heights, XL).
Immunoreactive bands were visualized by enhanced chemiluminescence(ECL). The
blots were exposed to hyperfilm. Results were quantified by scanning densitometer
(model 670, Bio-Rad). The data were normalized by actin and presented as the
percentage ofthe control protein levels within each group.
Measurement ofPKC activity. PKC activity was determined as previously

described (8,37). Briefly, after treatment, tissues were homogenized in buffer A
containing Tris-HCl 20 mM,sucrose 250 mM,EDTA 5 mM,EGTA 5 mM,PMSF 1

mM,P-mercaptoethanol 10 mM,and bcnzamide 1 niM. The homogenate was
centrifuged at 100,000g for 60 minutes at 4°C, and the supernatant was used as the
cytosolic fraction. The pellet corresponding to the membrane particulate fraction was

solubilized in buffer A containing Triton X-100 at a final concentration of0.1% by
stirring on ice for 45 minutes at 4°C,followed by centrifugation at 100,000g for 60
minutes at 4°C to remove insoluble membrane particles. Cytosolic and solubilized

membrane fractions were applied to DEAE-cellulose columns, which had been preequilibrated with buffer A including 0.1% Triton X-100. The DEAE columns were

washed with 5 mL of buffer A and 5 mL of buffer B containing Tris-HCl 20 mM,sucrose
250 mM,EDTA 1 mM,EGTA 1 mM,PMSF 1 mM,p-mercaptoethanol 10 mM,and
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benzamide 1 mM,and 0.1% Triton X-100. PKC was eluted with 2 mL of buffer B

including 400 mM NaCl. Protein concentrations were determined with a protein assay kit
(Bio-Rad). PKC activity was determined in the cytosol and soluhilized membrane

particulate fractions using a PKC ELISA assay that utilizes a synthetic peptide and a
monoclonal antibody that recognizes the phosphorylated form ofthe peptide (Upstate
Biotech).

Simultaneous measurement of[Ca /, and tension. Simultaneous recordings of

contraction and free intracellular calcium concentration([Ca^^JO in the same tissue were
conducted as described previously (36,43). Briefly, the arterial ring was attached to an
2_|_

isometric force transducer in a 5-ml tissue bath moimted on a CAF-110 intracellular Ca

analyzer (Jasco, Tokyo, Japan). The tissue was equilibrated in Krebs' buffer under a
resting tension of 0.5 g for 40 min. The ring was then loaded with 5|aM fura 2acetoxymethyl ester (fura 2-AM)for 3 h in the presence of0.02% Cremophor EL at room

temperature(25 °C). After loading, the tissue was washed with Krebs' solution at 37 °C
for 30 min to allow for hydrolysis offura-2 ester groups by endogenous esterase.
Contractile tension and fura-2 fluorescence were measured simultaneously at 37 °C in the
same tissue. The tissue was illuminated alternatively(125 Hz)at excitation wavelengths
of 340 and 380 nm,respectively, by means oftwo monochromators in the light path of a
75-w Xenon lamp. Fluorescence emission from the tissue was measured at 510 nm by a

photomultiplier tube. The fluorescence intensity at each excitation wavelength (F340 and
F380, respectively) and the ratio ofthese two fluorescence values (R340/380) were recorded
with a time constant of250 ms and stored with the force signal on a computer.
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Materials. Phenylephrine,PDBu,serotonin, PD-98059, staurosporine, and

calphostin C were obtained from Sigma Chemical(St. Louis, MO). All electrophoretic
and immunoblot reagents were from Bio-Rad Laboratories(Richmond, CA). Fura 2-AM
was obtained from Molecular Probes(Eugene, OR). PKC activity ELISA assay kit was

obtained from Upstate Biotech(Lake Placid, NY). All drugs were prepared fresh each

day and kept oh ice throughout the experiment.
Data analysis. Concentration-response curves were analyzed by computerassisted nonlinear regression to fit the data using GraphPad Prism (GraphPad software,

San Diego, CA). Results were expressed as means ± S.E.M. obtained from the number
(n)of experimental animals given. Differences were evaluated for statistical significance
(P < 0.05) by one-way ANOVA and paired Student t-test.
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Results

Effect ofPD-98059 on agonist-mediated contractions. Fig. 1 shows the effect

ofPD-98059 on phenylephrine-induced contraction ofthe uterine artery. PD-98059
showed no effect on basal tension in both nonpregnant and pregnant uterine arteries. As
depicted in Fig. 1, PD-98059 did not effect phenylephrine-induced contractions in

nonpregnant uterine arteries(pDi: 5.76 ± 0.12 vs. 5.50 ± 0.14,P > 0.05), but significantly

shifted the phenylephrine concentration-response curve to the right in pregnant uterine
arteries (pD2: 6.25 ± 0.02 V5. 5.44 ± 0.24,P < 0.05). The maximal response was not
effected (Fig. 1). Removal ofthe endothelium did not change the inhibition of PD-98059
on phenylephrine-induced contractions (data not shown).

Unlike its lack of effect on phenylephrine in nonpregnant uterine arteries, PD-

98059 significantly decreased 5-HT-induced contractions in nonpregnant uterine arteries

(pD2: 6.87 ± 0.19 v^. 6.32 ± 0.06,P < 0.05)(Fig. 2,lower panel). Pregnancy did not
change the PD-98059-mediated inhibition of 5-HT-induced contractions of the uterine

artery(pD2: 6.23 ± 0.03 vi'. 5.61 ± 0.23,P < 0.05)(Fig. 2, upper p^el).

Fig. 3 depicts the effect ofPD-98059 on protein kinase C(PKC)-mediated
contractions induced by PDBu in the uterine artery. PDBu produced a dose-dependent
contraction in both nonpregnant and pregnant uterine arteries. However,PDBu was 10-

time more potent in contracting nonpregnant than pregnant uterine arteries (pD2: 6.64 ±
0.07 V5. 5.62 ± 0.17,P < 0.05), and produced significantly higher maximum response in
nonpregnant(73.9 ± 14.3%)than pregnant(31.6 ± 4.0%)uterine arteries(P < 0.05). PD98059 did not effect PDBu-mediated contractions in nonpregnant uterine arteries (pD2;
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6.64 ± 0.07 vi'. 6.78 ± 0.06; maximum response: 73.9 ± 14.3% V5. 89.3 ± 22%,P > 0.05).

In contrast, PD-98059 significantly increased contractile sensitivity ofPDBu(pD2: 6.32 ±
0.20 vs. 5.62 ± 0.17,P < 0.05)and its maximum response (60.3 + 8.8% V5. 31.6 ± 4.0%,
P < 0.05)in pregnant uterine artery. Thus,PD-98059 minimized the difference in PDBu-

mediated contractions between nonpregnant and pregnant uterine arteries (Fig. 3). PKC

activity was measured in tissue fractions of pregnant uterine artery smooth muscle. As
shown in Fig. 4,PDBu significantly increased particulate/cytosolic PKC activity ratio,
which was blocked by both staurosporine and calphostin C. PD-98059 had no effect on

the resting P/C PKC activity ratio, but significantly enhanced PDBu-stimulated PKC
activity (Fig. 4).
The effect ofPD-98059 on KCl-induced contractions of uterine arteries is shown

in Fig. 5. In contrast to its effect on agonist-mediated contractions, PD-98059 had no

effect on KCl-induced contractions in both nonpregnant and pregnant uterine arteries.

From the data presented in Fig. 5,the pDa values of kci were 1.45 + 0.01 and 1.48 +
0.06 for the control and PD-98059-treated pregnant uterine arteries, and 1.47 ± 0.01 and
1.50 ± 0.08 for the control and PD-98059-treated non-pregnant uterine arteries.
Effect of ai-adrenergic agonist on the ERK activation. Fig. 6 shows total ERK-

1/2 protein levels in nonpregnant and pregnant uterine arteries, and demonstrates that
pregnancy is associated with an increase in ERK-2 protein levels in the uterine artery. To
demonstrate that the effect ofPD-98059 observed in the contraction was associated with

inhibition ofERK activation, we measured the phenylephrine-induced phosphorylation of

ERK using an ERKl/2 phospho-MAP kinase antibody. Fig. 7 depicts data from
experiments in which pregnant uterine artery rings in tissue baths were exposed to
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phenylephrine(3 pM)following PD-98059 pre-treatment(30 min)or the vehicle
(DMSO)alone. The tissues were treated with phenylephnne for 5 min followed by
immediately frozen in liquid nitrogen to stop the reaction. As shown in Fig. 7,
phenylephrine significantly increased tyrosyl-phosphorylation oftwo proteins with
molecular weights of44 kDa(207% above control) and 42 kDa(236% above control).

PD-98059 alone did not affect basal p44/p42 MAP kinase phosphorylation, but
significantly inhibited phenylephrine-induced tyrosyl-phosphorylation of both ERKl and
ERK2 by 50% and 53%,respectively(Fig. 7).

Effect ofPD-98059 on phenylephrine-induced changes in fCa^^Jiund

sensitivity. To examine the potential effect ofERK on agonist-mediated Ca^"^

concentration and Ca^^ sensitivity, contractile tension and [Ca^^]; were measured
simultaneously in the same tissue as described in the Methods. In the arterial rings

loaded with fura-2, an increase in [Ca^"^,resulted in an increase in F340, a decrease in
F380, and an increase in R340/38o- Typical traces of simultaneous measurement of

phenylephrine-stimulated increase in [Ca^^], and muscle tension development in the
pregnant uterine artery are shown in Fig. 8. Because preliminary studies demonstrated

that 10 pM and 30 pM PD-98059 completely blocked phenylephrine-induced
contractions in this preparation, subsequent studies were performed using 3 pM PD-

98059. PD-98059 significantly decreased basal [Ca^^], as evidenced ofreducing fura-2
fluorescence ratio (R340/380) from 0.198 ± 0.012 to 0.146 ± 0.008(P < 0.05) in pregnant,
but not nonpregnant(0.099 ± 0.01 vs. 0.092 ± 0.009,P > 0.05) uterine arteries. Fig. 8

shows the real time effect ofPD-98059 on phenylephrine-induced [Ca^"^],response and
contractile tension in intact pregnant uterine arteries. As shown in Fig. 8,10 pM
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phenylephrine caused an increase in [Ca^"^], and contractile tension simultaneously. After
washing and recovery,the same tissue was pretreated with 3 pM PD-98059 for 30 min,
and then challenged again with 10 pM phenylephrine. Both the phenylephrine-induced

[Ca^"^],and contractile tension were significantly reduced in the presence of PD-98059
(Fig. 8). The responses to phenylephrine were completely recovered after the removal of
PD-98059(Fig. 8). Quantitative analysis ofthe data revealed that PD-98059 decreased

phenylephrine-induced contractile tension and [Ca^"^]iby 71% and 53%,respectively(P <
0.05, paired f-test)(Fig. 9). In addition, the simultaneous measurement of[Ca^^],with
tension in the same intact tissue allowed us to determine directly the precise relationship

between fura-2 R340/380 and tension in the uterine artery and thus to estimate Ca^^
sensitivity of myofilaments. As shown in Fig. 9,the contraction of pregnant uterine

artery at a given amount ofincrease in [Ca^"^],mediated by phenylephrine was
significantly decreased by PD-98059. In contrast, PD-98059 had no effect on [Ca^'^],and
Ca2-i- sensitivity induced by phenylephrine in nonpregnant uterine arteries (data not
shown).
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Discussion

The present study has demonstrated that the ERK pathway plays a key role in
the regulation of uterine artery contractility. More importantly, the effect ofERK on the
uterine artery is regulated by pregnancy. There are several important observations in the
present study. First, among the several agonists tested, PD-98059 selectively inhibited 5HT-induced contractions in nonpregnant uterine artery. Second, pregnancy selectively

augmented the inhibition ofPD-98059 on ai-adrenoceptor-, but not 5-HT-, induced
contractions in uterine arteries. Third, in agreement with the previous finding in rat

thoracic aorta(22), the PDBu-induced contraction was significantly attenuated in
pregnant uterine artery. PD-98059 did not effect the PDBu-mediated contraction in

nonpregnant uterine arteries, but significantly increased it in pregnant uterine arteries. In

accordance, PD-98059 significantly enhanced PDBu-stimulated PKC activity in pregnant

uterine artery. Fourth, PD-98059 had lio effect oh Kifcl-mediated contractions in both
nonpregnant and pregnant uterine arteries. Fifth, activation of ai-adrenoceptors increased
tyrosyl-phosphorylation of ERKl/2, which was blocked by PD-98059. Sixth, PD-98059-

mediated inhibition ofthe phenylephrine-induced contraction was associated with a

decrease in both intracellular Ca^"^ concentration and Ca^"^ sensitivity of contractile
proteins in the uterine artery.

The agonist-stimulated activation ofERK has been well documented in cultured

smooth muscle cells (16,21,28,29), and intact smooth muscle (3,10,23). The lack of

effect ofPD-98059 on KCl-induced contractions in both nonpregnant and pregnant
uterine arteries suggests that the fimction of Ca channels may not he regulated by the
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ERK pathway in uterine arteries. This is in agreement with several previous findings
(10,12,30,39). On the other hand, it was also reported that tyrosine kinase inhibitors

inhibited L-type voltage gated Ca^^ channels(4,23,40). Similarly, several previous
studies have explored the role ofERK in the regulation of agonist-mediated arterial

contractions in different animal models and arterial types, but the results are controversial
(10,13,15,32). The present finding that PD-98059 inhibited 5-HT-induced contractions
ofthe uterine artery is in agreement with the previous study in which 5-HT-mediated

contractions were inhibited by PD-98059 in rat aorta, mesenteric artery, and tail artery
(39). We have previously demonstrated that 5-HT-elicited contractions ofthe uterine

artery are mediated by the increase ofinositol 1,4,5-trisphosphate, leading to release of

Ca^^ fi"om intracellular stores(42,43). The present results suggest the involvement ofthe
ERK pathway in 5-HT-induced contractions ofthe uterine artery. It has been
demonstrated that 5-HT stimulates the activation of ERK 1/2 in arterial smooth muscle

(12,39). The finding that the inhibitions 5fPE)-986il on 5-HT-induced contractions
were not different in pregnant and nonpregnant uterine arteries suggest that the effect of
ERK on the 5-HT-mediated contraction is not regulated by pregnancy.
Unlike its effect on the 5-HT-mediated contraction, PD-98059 showed no effect
on the phenylephrine-induced contractions in nonpregnant uterine artery. This is contrary

to the previous finding in ferret aorta in which PD-98059 inhibited phenylephrine-

induced contractions(10). However,PD-98059 did not effect phenylephrine-induced
contractions in rat mesenteric resistance arteries (30). These results suggest that the role

ofERK in the ai-adrenoceptor-mediated contraction show a considerable heterogeneity
in vessel types. Nevertheless, PD-98059 did inhibit phenylephrine-mediated contractions
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in pregnant uterine artery. In consistent with the contraction results, Western analysis
indicated that phenylephrine increased protein tyrosyl-phosphorylation of both p42/p44

MAP kinase in pregnant uterine artery, which was blocked by PD-98059. These results
suggest that pregnancy up-regulates the coupling ofthe ERK pathway to aiadrenoceptor-mediated contractions in the uterine artery. Given that both 5-HT and aiadrenoceptor-mediated contractions share a common downstream signal, i.e. inositol

1,4,5-trisphosphate, in the uterine artery (19,42,43,44), it is intriguing that PD-98059
differentially regulated 5-HT and phenylephrine-induced contractions in uterine arteries.

This would suggest a specific coupling ofthe ERK pathway to individual receptor
signaling pathways. Although the cellular mechanisms for this selectivity are not clear at
present, it is postulated that scaffolding proteins may play an important role.

It is generally believed that during pregnancy the uterine vasculature acts as a

low-resistance shunt to accommodate the large increase in uteroplacental blood flow
required for normal fetal development. The mechMiSms for the attenuated vascular tone
may involve a decreased role of endogenous vasoconstrictors and/or an increased role of

both endogenous vasodilator and placental angiogenic factors (31,35,41). Given that aiadrenoceptors play a key role in moment-to-moment regulation of uterine vascular tone,
the finding that pregnancy selectively up-regulated the role ofERK in ai-adrenoceptor
(but not 5-HT)-mediated contractions in the uterine artery warrants a physiological

significance ofthe ERK pathway in the regulation of uterine artery contractility during
pregnancy. Nonetheless, it is not clear at present whether and to what extent the
enhanced ERK pathway in ai-adrenoceptor-mediated signaling affects the vascular tone
of pregnant uterine artery. It has been shown recently that the pregnancy-induced
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increase in uterine artery endothelial vasodilator production is mediated in part by a

marked alteration in signaling pathway including activation ofthe ERK pathway (7). The
present finding that the inhibition ofPD-98059 on the phenylephrine-induced contraction
was not changed with and without the endothelium in both pregnant and non-pregnant

uterine arteries suggests a less important role ofERK on the uterine artery endothelium.
The finding that the PDBu-induced contraction was significantly attenuated in
pregnant uterine artery is in agreement with previous results in rat thoracic aorta(22),
suggesting that the role ofPKC in the regulation of uterine vascular tone is down-

regulated during pregnancy. It has been well documented that PKC plays an important
role in the regulation ofthe sustained phase of contraction in vascular smooth muscle
(18). In consistent with the previous findings (1,15,30,39), PD-98059 had no effect on
the PDBu-induced contraction in nonpregnant uterine arteries. To our surprise, PD98059 significantly increased PDBu-induced contractions in pregnant uterine arteries. To

our knowledge, it has not been reported pr6vidusly that PD-98059 increases contractions
to any agonists examined. It has been proposed in several studies that PKC is an
upstream signal ofthe activation ofthe ERK pathway in the vascular smooth muscle
(24,25,26,27,29,30). In contrast, the present result that the PBDu-induced contraction
was increased after the ERK inhibition by PD-98059 would suggest a role for ERK in the

regulation ofPKC as a downstream signal in the uterine artery of pregnant animals. This

is supported by the finding that PD-98059 significantly enhanced PDBu-stimulated PKC
activity in pregnant uterine arteries. The finding that PD-98059 increased PDBu-induced

contractions of pregnant uterine arteries and eliminated its difference between

nonpregnant and pregnant uterine arteries is likely to have physiological significance, and

61

suggests that ERK may play a very important role in increased uterine blood flow by
suppressing the PKC-mediated contraction during pregnancy. Consistent with this
notion, the present study demonstrated a significant increase in ERK-2 protein levels in
pregnant, as compared with nonpregnant, uterine arteries. This is in agreement with our
recent findings in uterine artery endothelial cells in which pregnancy is associated with
an enhancement in ERK-2 signaling pathway (7,11).

Whereas the mechanisms underlying ERK-mediated inhibition ofPKC-induced
contractions are not clear at present, our study demonstrated that PD-98059 inhibited the

phenylephrine-mediated contraction by decreasing both phenylephrine-induced

intracellular Ca^"^ concentration and Ca^^ sensitivity. To our knowledge, our results are
the first to show a direct relation between PD-98059-mediated inhibitions of agonist•

9+

induced contraction and Ca

concentration in intact muscle. Previous studies have

suggested that PD-98059 inhibits agonist-induced contraction by decreasing Ca^^
sensitivity of contractile proteins throU]|h the ihhibitibn of ERK-mediated
phosphorylation of caldesmon (2,10,12,17,18). Studies in isolated smooth muscle cells

indicated that PD-98059 did not effect agonist-induced intracellular Ca^"^ concentration
(33,38). However,the effect ofPD-98059 on Ca^"^ concentration in intact smooth muscle
was not examined. We have developed a method to measure contractile tension and
94-

intracellular Ca concentration simultaneously in the same intact arterial ring (43). This

allowed us to directly determine the precise relationship between fura-2 R340/380 and

tension in the uterine artery, and thus to estimate not only Ca^"^ concentration but also
94-

Ca sensitivity of myofilaments with unimpaired excitation-contraction coupling
processes and retained regulatory targets for second messenger pathways. The present
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study clearly demonstrated that the PD-98059-mediated inhibition of phenylephrine-

induced contraction was associated with a decrease in both Ca^^ concentration and Ca^^
sensitivity in the uterine artery. Our findings suggest, therefore, that, in addition to the

Ca^^-independent pathway as proposed previously, the ERK signaling pathway also
involves the Ca^"^-dependent component of vascular contractions. It is noteworthy that
PD-98059 decreased not only the agonist-induced Ca^^ concentration but also the basal
Ca^"^ concentration. This raises the possibility that ERK may play a role in the regulation
of basal tone ofthe uterine artery.

In summary,the results indicate that ERK plays an important role in the
regulation of uterine artery contractility, and its effect is agonist-dependent. More

importantly, pregnancy selectively enhances the role ofERK in ai-adrenoceptormediated contractions and its effect in suppressing the protein kinase C-mediated

contraction in the uterine artery. In addition, both the Ca^"^ dependent and independent
components are involved in the ERK pathway in th6 literine artery. The physiological
role ofthe ERK pathway and it mechanisms in the adaptation of uterine vascular
reactivity to pregnancy are important avenues for future studies.
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Figure 1. Effect of PD-98059 on phenylephrine-induced contraction in ovine

uterine arteries. Arterial rings were pretreated with 30 pM PD-98059 or with the

vehicle DMSO (Control)for 30 min and then subjected to the cumulative addition of

phenylephrine in Krebs' solution. Data are expressed as percentages of contraction
produced by 120 mM KCl,and each point represents mean + SEM offour animals. The

pD2("log ECso) values were presented in the text. Upper panel: pregnant uterine artery.
Lower panel: nonpregnant uterine artery.
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Figure 2. Effect of PD-98059 on 5-HT-induced contraction in ovine uterine arteries.

Arterial rings were pretreated with 30 pM PD-98059 or with the vehicle DMSO (Control)
for 30 min and then subjected to the cumulative addition of 5-HT in Krebs' solution.

Data are expressed as percentages of contraction produced by 120 mM KCl,and each

point represents mean ± SEM offour animals. The pD2(-log EC50)values were presented
in the text. Upper panel: pregnant uterine artery. Lower panel: nonpregnant uterine
artery.
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Figure 3. Effect of PD-98059 on PDBu-induced contraction in ovine uterine arteries.

Arterial rings were pretreated with 30 pM PD-98059 or with the vehicle DMSO (Control)
for 30 min and then subjected to the cumulative addition ofPDBu in Krehs' solution.

Data are expressed as percentages of contraction produced by 120 mM KCl, and each

point represents mean ± SEM offour animals. The pD2(-log EC50) values were presented

in the text. Upper panel: pregnant uterine artery. LoWer panel: nonpregnant uterine
artery.
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Figure 4. Effect of PD-98059 on PDBu-stimulated jPKC activity in ovine uterine
artery. Pregnant uterine arteries were pretreated with 30 pM PD-98059(PD),0.1 pM
V

staurosporine (Stan), and 0.1 pM calphostin C(Calp)for 30 min before the addition of

PDBu(3 pM,30 min). PKC activity in the cjdosolic and particulate fractions was
determined as described in the Methods. Data are means ± SEM offour animals, a,P <
0.05, vs. rest; b,P < 0.05, V5. PDBu alone.
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Figure 5. Effect of PD-98059 on KCl-induced contraction in ovine uterine arteries.

Arterial rings were pretreated with 30 pM PD-98059 or with the vehicle DMSO (Control)
(

for 30 min and then subjected to the cumulative addition of KCl in Krebs' solution. Data

are mean + SEM offour to six animals. The pDa (-log EC50) values were presented in the
text. Upper panel: pregnant uterine artery. Lower panel: nonpregnant uterine artery.
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Figure 6. Effect of pregnancy on total ERK-1/2 protein levels in uterine arteries.

Upper panel shows scanned images of representative anti-p44/42-MAP kinase
immunoblot from pregnant(P)and nonpregnant(NP)uterine arteries. The two bands

detected correspond to the 44-kDa isoform(ERKl)and 42-kDa isoform(ERK2). Middle
panel shows ERK2(42-kDa)determined by densitometry. Lower panel shows ERKl
(44-kDa)determined by densitometry. Data are means ± SEM of ten animals. *,P <
0.05, vs. nonpregnant.
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Figure 7. Effect of phenylephrine on ERK activation in uterine arteries. Pregnant
uterine arteries were pretreated with 30 pM PD-98059(PD)or with the vehicle DMSO
(control, C)for 30 min before the addition of phenylephrine (PE). When the contraction

reached its steady state(PE alone or PE +PD-98059 group)(5 min)the rings were snap
frozen in liquid N2. Upper panel shows scanned images of representative anti-phosphoMAP kinase immunoblot from uterine artery treated as above. The two bands detected

correspond to the 44-kDa isoform(ERKl)and 42-kDa isoform(ERK2). Middle panel
shows phosphorylation ofERK2(42-kDa) deterihih^d by densitometry, and expressed

relative to a-actin density. Lower panel shows phosphorylation ofERKl (44-kDa)
determined by densitometry, and expressed relative to a-actin density. Data are means ±
SEM offour animals, a,P < 0.05, control V5. PE; b,P < 0.05,PE V5. PE+PD-98059.
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Figure 8. Effect of PD-98059 on phenylephrine-induced contraction and

intracelluiar Ca^^ in the uterine artery. Representative traces show the effect ofPD98059 on phenylephrine (PE)-induced [Ca^"^],(fura-2 signal RG40/f380, upper panel) and
contraction (lower panel)recorded simultaneously in the same tissue of pregnant uterine

artery loaded with fura-2. The tissue was stimulated first with 10 pM phenylephrine.
After washotit, it was treated with 3 pM PD-98059 for 30 min,followed by the same
\

concentration of phenylephrine. After wa§hout> thi lime tissue was stimulated with
phenylephrine again.
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Figure 9. Effect ofPD-98059 on phenylephrine-induced intracellular Ca^"^
concentration and Ca sensitivity in the uterine artery. Phenylephrine(10 pM)-

induced [Ca^"^]j(fura-2 signal Rf34o/G8o) and contraction were recorded simultaneously in
the absence (control) or presence ofPD-98059(3 pM for 30 min)in the same tissue of
pregnant uterine artery loaded with fura-2 as shown in Fig. 7. Data are means + SEM of
four animals. * P < 0.05.
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CHAPTER THREE

ERK-Mediated Uterine Artery Contraction: Role of Thick and Thin
Filament Regulatory Pathways

DaLiao Xiao, William J. Pearce,Lawrence D.Longo,and Lubo Zhang

This chapter appeared in publication in the American Journal ofPhysiology(Heart Circ
Physiol) 286: H1615-H1622,2004.
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Abstract

We have demonstrated that extracellular signal-regulated kinase(ERK)plays an

important role in the regulation of uterine artery contraction. The present study tested the
hypothesis that ERK regulates both thick and thin filament regulatory pathways in the
9+

9+

uterine artery. Isometric tension, intracellular free Ca concentration([Ca ],), and 20-

kDa myosin light chain(LC20)phosphorylation were measured simultaneously in uterine
arteries isolated from near-term (140 days gestation) pregnant sheep. Phenylephrine

produced time-dependent increases in [Ca^^],and LC20 phosphorylation that preceded the
contraction, which were inhibited by the MEK(ERK)inhibitor PD098059. In addition,

PD098059 decreased the intercept ofthe regression line of LC20 phosphorylation V5

[Ca^^(, but increased the rate oftension development V5 LC20 phosphorylation. Unlike
phenylephrine, phorbol 12,13-bibutyrate(PDBu)produced contractions without changing
[Ca ], or LC20 phosphorylation. PD098059 potentiated PDBu-induced contractions

without affecting [Ca^"^], and LC20 phosphorylation. PDBu produced time-dependent
increases in phosphorylation ofERK42/44, and ERK-dependent phosphorylation of

caldesmon at Ser^^^ in the uterine artery. PD098059 blocked PDBu-mediated
phosphorylation ofERK42/44 and caldesmon. The results indicate that ERK may regulate

force by a dual regulation ofthick and thin filaments in uterine artery smooth muscle.

ERK potentiates the thick filament regulatory pathway by enhancing LC20

phosphorylation via increases in [Ca^^,and Ca^"^ sensitivity of LC20 phosphorylation. In
contrast, ERK attenuates the thin filament regulatory pathway, and suppresses

contractions independent of changes in LC20 phosphorylation in the uterine artery.
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Introduction

Smooth muscle contraction is regulated by phosphorylation and
dephosphorylation ofthe 20-kD regulatory light chain of myosin(LC20)(21,25, 39).

Phosphorylation of LC20 is regulated primarily by an increase in intracellular free Ca^"^

concentration ([Ca^"^],), resulting in activation of myosin light chain kinase(MLCK)and
I

subsequent phosphorylation of LC20. Dephosphorylation of LC20 by myosin light chain
phosphatase(MLCP)results in smooth muscle relaxation. The extent of LC20

phosphorylation and, hence, ofthe amplitude offorce production depends on the balance

ofthe activities of MLCK and MLCP.In addition to thick filament regulation, many
studies have demonstrated dissociation between LC20 phosphorylation and cross-bridge
cycling rates/tension development(6,12,18,20, 32), suggesting an additional thin
filament regulation in smooth muscle contraction(21,33).

Extracellular signal-regulated kinase(ERK.)has been proposed to regulate
smooth muscle contraction(2,11,16,17,26,52, 55, 57). Different signaling transduction
mechanisms have been reported in ERK-mediated regulation of smooth muscle
contraction. Previous studies showed that the MEK(ERK)inhibitor, PD098059 did not

affect agonist-induced intracellular Ca^^ concentration in isolated smooth muscle cells,

but inhibited agonist-induced smooth muscle contraction by decreasing Ca^^ sensitivity
of eontractile proteins(1,2,11,17,21, 38,49). It has been proposed that ERK mediates
smooth musele contraction through the thin filament regulatory pathway by

phosphorylation ofcaldesmon(2,21, 33). However, by measuring intracellular Ca^"^
concentration and tension simultaneously in the intact tissue, our recent studies clearly
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demonstrated that PD098059-mediated inhibition of phenylephrine-induced contraction
was associated with a decrease in both intracellular Ca

Concentration and Ca

sensitivity in sheep uterine artery smooth muscle (55). This suggests that, in addition to

Ca^"^-independent pathways as proposed previously, the ERK signaling pathway also
involves Ca -dependent components of vascular contractions. Similarly, recent studies
in porcine carotid artery suggested that ERK might regulate force in arterial smooth
muscle by inhibiting LC20 phosphorylation (8).

Recently, we have demonstrated that ERK plays an important role in the

regulation of uterine artery contraction, and the effect ofERK on the uterine artery is
altered during pregnancy (55). In the present study, we tested the hypothesis that ERK

regulates uterine artery contraction through both thick and thin filament regulatory
pathways. We examined the effects ofthe MEK(ERK)inhibitor PD098059 on both

phenylephrine- and phorbol 12,13-dibutyrate(PDBu)-induced increases in [Ca^"^]i, LC20
phosphorylation, and contractile tension in uterine arteries obtained from pregnant sheep.
We also examined phosphorylation ofERK and ERK-dependent phosphorylation ofthe
thin filament regulatory protein caldesmon. The present study provides evidence that
ERK potentiates the thick filament regulatory pathway by enhancing LC20
phosphorylation, but attenuates the thin filament regulatory pathway by suppressing
contractions independent of changes in LC20 phosphorylation in the uterine artery.
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Methods

Tissue preparation. Pregnant(-140 days gestation) sheep were anesthetized

with thiamylal(10 mg/kg)administered via the external left jugular vein. The ewes were
then intubated, and anesthesia was maintained on 1.5% to 2.0% halothane in oxygen
throughout the surgery. An incision in the abdomen was made and the uterus exposed.
The uterine arteries were isolated, removed without stretching, and placed into modified

Krebs solution(pH 7.4) ofthe following composition (in mM): 115.21 NaCl,4.7 KCl,
1.80 CaCl2,1.16 MgS04,1.18 KH2PO4,22.14 NaHCOs,0.03 EDTA,and 7.88 dextrose.

The Krebs solution was oxygenated with a mixture of95% oxygen-5% carbon dioxide.
After the tissues were removed, animals were killed with euthanasia solution(T-61,

Hoechst-Roussel; Somerville, NJ). All procedures and protocols used in the present study
were approved by the Animal Research Committee of Loma Linda University, and

followed the guidelines ofthe National Institutes Of Health Guidefor the Care and Use of
Laboratory Animals.
Contraction studies. The fourth branches of main uterine arteries were

separated from the surroimding tissue, and cut into 2-mm ring segments. The small
branches ofthe main uterine artery were chosen because they are much closer in
characteristics to arterioles and play a substantial role in vascular resistance. Isometric

tension was measured in Krebs' solution in a tissue bath at 37 °C, as described previously

(55). After 60 min of equilibration, each ring was stretched to the optimal resting tension
as determined by the tension developed in response to potassium chloride(120 mM)
added at each stretch level. Tissues were pretreated with either PD098059(30 pM)or
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vehicle(DMSO)for 30 min,followed by stimulation with phenylephrine or PDBu.
Tension was recorded with an on-line computer. To measure LC20 phosphorylation
simultaneously in the same tissues, arterial rings were snap-frozen with liquid Ni-cooled
clamps at the indicated times, and immersed in a dry ice-acetone slurry containing 10%
trichloroacetic acid(TCA)and 10 mM DTT mixture. Rings were stored at -80°C until
used.

Measurement ofLC20phosphorylation. Tissues were brought to room
temperature in the dry ice-acetone-TCA-DTT mixture, and then washed three times with

ether to remove the TCA. Tissues were then extracted in 100 pi of sample buffer
containing 20 mM Tris base and 23 mM glycine(pH 8.6), 8.0 M urea, 10 mM DTT,10%

glycerol and 0.04% bromophenol blue, as previously described (8,28). Samples(20 pi)
were electrophoresed at 120 mA for 2.5 h after a 30 min pre-run in 1.0 mm mini-

polyacrylamide gels containing 10% arcelamide-0.27% bisacrylamide,40% glycerol and

20 mM Tris Base(pH 8.8). Proteins were treihiifeijt'^d to nitrocellulose membranes and
V.

subjected to immunoblot with a specific LC20 antibody (1:500, Sigma). Goat anti-mouse

IgG conjugated with horseradish peroxidase was used as a secondary antibody (1:2000,
Calbiochem). Bands were detected with enhanced chemiluminescence(ECL), visualized
on films, and analyzed with KODAK Electrophoresis Documentation and Analysis

System and KODAK ID Image Analysis Software. Moles phosphate per mole light chain

was calculated by dividing the density ofthe phosphorylated band by the sum ofthe
densities ofthe phosphorylated plus the unphosphorylated bands.
Simultaneous measurement of

and tension. Simultaneous recordings of

contraction and [Ca ]/ in the same tissue were conducted as described previously (56).
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Briefly, each arterial ring was attached to an isometric force transducer in a 5-ml tissue
bath moimted on a CAF-110 intracellular

analyzer (Jasco; Tokyo, Japan). The tissue

was equilibrated in Krebs buffer under a resting tension of0.5 g for 40 min. The ring was
then loaded with 5 pM fura 2-AM for 3 h in the presence of0.02% Cremophor EL at
room temperature(25 °C). After loading, the tissue was washed with Krebs solution at 37
°C for 30 min to allow for hydrolysis offura 2 ester groups by endogenous esterase.
Contractile tension and fiira 2 fluorescence were measured simultaneously at 37 °C in the

same tissue. The tissue was illuminated alternatively(125 Hz)at excitation wavelengths

of340 and 380 nm,respectively, by means oftwo monochromators in the light path of a

75-w xenon lamp. Fluorescence emission from the tissue was measured at 510 nm by
photomultiplier tube. The fluorescence intensity at each excitation wavelength (F340 and
F380, respectively) and the ratio ofthese two fluorescence values (R340/380) were recorded

with a time constant of250 ms and stored with the force signal on a computer.

Western immunoblotting anMysis. Arterial rings were equilibrated in the tissue
bath and the optimal tensions were obtained as described above. The tissues were then

incubated for 30 min with PD098059(30 pM)or vehicle alone in the organ bath(37 °C).
After incubation,they were stimulated with PDBu(5 pM). The reaction was stopped at
various times by snap-freezing the tissues in liquid nitrogen and stored at -80 °C until

used. Protein levels of phosphorylated ERK42,ERK44, and caldesmon at Ser'^^ were
determined by Western blot analysis as previously described (55). Briefly, samples with
equal protein were loaded on 10%(ERK42/44) and 7.5%(caldesmon)SDS-PAGE,
separated by electrophoresis, and transferred to nitrocellulose membranes. The

membranes were incubated with the antibodies against phospho-ERK42/44 (Tyr^^^/tyr^*^"^)
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and phospho-caldesmon (Ser^^^), followed by secondary antibodies of horseradish
peroxidase-conjugated goat anti-rabbit. Proteins were visualized with enhanced
chemiluminescence reagents, and the blots were exposed to hyperfilm. Results were

quantified with KODAK Electrophoresis Documentation and Analysis System and
KODAK ID Image Analysis Software. The data were normalized by actin.

Materials. Phenylephrine,PDBu,PD098059,and monoclonal anti-myosin
(light chains 20K)were obtained ftom Sigma (St. Louis, MO).Phospho-ERK42/44

(Tyr202/tyr204)

^gj.g

(^gp signaling Technology(Beverly, MA). Phospho-

caldesmon (Ser^^^) antibody was fi-om Santa Cruz Biotechnology(Santa Cruz, CA). All
electrophoretic and immunoblot reagents were from Bio-Rad. Fura 2-AM was obtained

ftom Molecular Probes(Eugene, OR). Other reagents were of anal5dical grade or better,
and were purchased from Sigma or Fisher Scientific. All chemicals were prepared fresh
each day and kept on ice throughout the experiment.
Data analysis. Data were analyzed by cdih|)uter-assisted linear or nonlinear

regression to fit the data using GraphPad Prism (GraphPad software; San Diego, CA).
Residts were expressed as means ± SE obtained from the number(n)of experimental
animals given. Differences were evaluated for statistical significance(P < 0.05) by one
way ANOVA and Student's r-test.
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Results

Effect ofPD098059 on phenylephrine-induced increases in [C(^^]i, LC20
phosphorylation and tension. Phenylephrine produced time-dependent increases in

[Ca^^]/, LC20 phosphorylation, and tension development in the uterine artery (Fig. 1). The

tension development was preceded by both [Ca^"^, and LC20 phosphorylation. Although
the agonist-induced tension was sustained up to 5 min, both LC20 phosphorylation and

[Ca^"^/ progressively declined to a steady state of50% and 65%,respectively, oftheir
peak values. As also illustrated in Fig. 1, PD098059 significantly inhibited

phenylephrine-induced increase in [Ca^^];in the uterine artery, and decreased the peak
level to 56% that of control. Likewise,PD098059 significantly decreased the rate of

phenylephrine-mediated LC20 phosphorylation and the maximum phosphorylation in the
uterine artery. The peak phosphorylation level was significantly decreased to 35.6 ± 8.7%
that of control, and the time to the peak was delayed by 20 s, as compared to the control.

Although PD098059 did not change the time to the peak of phenylephrine-induced force
development, it slowed the initial rate oftension development and significantly decreased
the contractile tension, as compared to the control.

Effect ofPD098059 on LC20phosphorylation/[C(^^]i relation. Contractions of
smooth muscle can be regulated by altering the dependence of LC20 phosphorylation on

[Ca2"i"]/, or the dependence offorce on LC20 phosphorylation. To determine the potential

role ofERK in the regulation of Ca^^ sensitivity of LC20 phosphorylation at fixed [Ca^^„
we examined the effect ofPD098059 on the relation of phenylephrine-stimulated

increases in [Ca J, and LC20 phosphorylation in the uterine artery. As shown in Fig. 2,
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PD098059 did not affect the slope (LCp/Rf34o/38o)(from control; 13.5 ± 2.8, n = 9 to the
treatment group: 11.6 ± 1.2, n = 5;P > 0.05), but significantly decreased the intercept
from 0.164 ± 0.054 to 0.0097 ± 0.0019(P < 0.05). This downward shift in the curve has

the effect of showing a decreased LC20 phosphorylation at any given intracellular Ca^"^
level.

Effect ofPD098059 onforce/LC2o phosphorylation relation. Although the

majority of stimuli result in a unique relation between LC20 phosphorylation and force in
smooth muscle, collateral regulation via thin fileiments in modulating contraction can
either increase or decrease the force/LC2o phosphorylation ratio. We further examined the

role ofERK in the regulation ofcontractions independent of changes in LC20
phosphorylation, by evaluating the effect ofPD098059 on the relation between

phenylephrine-stimulated increases in LC20 phosphorylation and force measured

simultaneously in the same tissue. Phenylephrine-induced tensions were plotted against

their corresponding phosphorylated LC20 levels 6fthe initial rising phases in control and
PD098059-treated tissues, respectively(Fig. 3A). As shown in Fig. 3A,PD098059

caused a leftward shift in the force/LC2o phosphorylation relation, suggesting that tension
developed at a given level of LC20 phosphorylation in PD098059-treated tissues was
increased, as compared with that in control tissues. Because the relation between

phenylephrine-stimulated LC20 phosphorylation and force development was nonlinear in
both control and PD098059-treated tissues, analysis was performed to determine the

levels of LC20 phosphorylation ofcontrol and PD098059-treated tissues at corresponding
tensions developed (from 0.4 to 2.8 g). As shown in Fig. 3B,there was a linear relation
between the levels of LC20 phosphorylation of control and PD098059-treated tissues at
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corresponding tensions, with the slope(0.456 ± 0.008)significantly lower than that ofthe
line ofidentity, confirming that the amount offorce produced per phosphorylated LC20
was enhanced by PD098059.
Effect ofPD098059 on PDBu-stimulated

LC20phosphorylation and

tension. Compared to phenylephrine,PDBu stimulated a much slower development of
tension, which reached the maximum at 20 min. In contrast to phenylephrine,PDBu did

not significantly increase either [Ca^"^]/(data not shown)or LC20 phosphorylation in the
uterine artery(Fig. 4). Simultaneous measurement of[Ca^"^], and contractions showed

that PD098059 increased PDBu-induced contractions without changing [Cs^*]i(data not
shown). The effect ofPD098059 on PDBu-induced contraction and LC20 phosphorylation
was examined in the tissues in which contractile tension and LC20 phosphorylation were

measured simultaneously in the same tissue. As shown in Fig. 4,PD098059 augmented
the PDBu-mediated contractions over the time period examined, but did not change LC20
phosphorylation.

Effect ofPD098059 on PDBu-stimulated phosphorylation ofERK42/44 and

caldesmon. PDBu produced time-dependent increases in phosphorylation ofERK42/44

(Fig. 5), and ERK-dependent phosphorylation of caldesmon at Ser^^^ in the uterine artery
(Fig. 6). PD098059 blocked PDBu-mediated phosphorylation of ERK42/44 and caldesmon
(Fig. 5 & Fig. 6).
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Discussion

ERK and thickfilament regulation. Smooth muscle contraction is regulated by
both thick and thin filament regulatory pathways. Thick filament regulation is mediated

by both Ca^^-dependent mechanisms that lead to activation of myosin light chain kinase
(MLCK)and LC20 phosphorylation, and Ca^"^-independent mechanisms that involve
inactivation of myosin light chain phosphatase(MLCP)and a decrease in LC20

dephosphorylation. In the present study, we examined the temporal relationships among
[Ca

LC20 phosphorylation, and isometric force in the pregnant uterine artery, and.

Consistent with previous findings, demonstrated that phenylephrine produced a time-

dependent increase in [Ca^"^], and LC20 phosphorylation that preceded the contraction. We
found that the decrease in phenylephrine-induced force development caused by
PD098059 was preceded with a reduction in LC20 phosphorylation, suggesting a role for

ERK in thick filament regulation. Similar results Wife obtained in porcine carotid artery,
in which PD098059-mediated inhibition ofendothelin-1-induced contraction was

associated with a reduction in LC20 phosphorylation (8).
Previous studies in isolated smooth muscle cells have suggested that ERK does

not regulate [Ca^"^]/(38,49). However,our recent studies in the intact arterial rings, in
•

^I

which[Ca ], and contractile tension were measured simultaneously in the same tissue,
demonstrated clearly that PD098059-mediated inhibition of phenylephrine-induced

contraction was associated with a decrease in both [Ca^"^], and Ca^^ sensitivity in the
uterine artery(55). This suggests that, in addition to the Ca^"^-independent pathway as
previously proposed (1,2,11,17,21,33),the ERK signaling pathway also involves the
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Ca^^-dependent components of vascular contractions. Consistent with our previous
findings, the present study demonstrated that PD098059 inhibited phenylephrine-induced

increase in [Ca^"^,. The mechanisms involved in ERK-mediated regulation of[Ca^^]; are
not clear at present. Given the finding that PD098059 did not affect force development
elicited by KCl depolarization(8, 52, 55), it is likely that ERK may regulate the release

of Ca^"^ from intracellular pools, but not Ca^"^ entry via L-type Ca^"^ charmels. Because
LC20 phosphorylation is primarily regulated by [Ca^"^]/, our results suggest that ERK may

regulate LC20 phosphorylation, in part, through modulating [Ca^^],.
In addition, we foimd that PD098059 significantly decreased Ca^"^ sensitivity of
LC20 phosphorylation in response to phenylephrine, i.e. less LC20 phosphorylation at the

given [Ca^^], in the presence ofPD098059. Because alterations in the activities of MLCK

or MLCP at fixed [Ca^^], will affect the Ca^^ sensitivity of LC20 phosphorylation, the
results suggest that, in addition to the regulation of MLCK activity through changes in

[Cs^*]i, ERK may also regulate either MLCK or/ahd MLCP activities independent of

changes in [Ca^^],-. The finding that PD098059 decreased the intercept without affecting
the slope ofLC20 phosphorylation vj'. [Ca^"^], relation suggests that ERK may have a
positive tonic effect on Ca^^ sensitivity of LC20 phosphorylation, but may not affect the
agonist-mediated Ca^"^ sensitivity. Both MLCK and MLCP can be involved in the

regulation of Ca^"^ sensitivity of LC20 phosphorylation, and MLCP may be primarily
involved in agonist-induced Ca^"^ sensitization (39). Although the present study cannot
rule out effects on MLCP,we speculate that the tonic effect ofERK on Ca^"^ sensitivity
observed in the present study may be mediated by an increase in MLCK activity. It has
been demonstrated that purified, constitutively active ERK1/2 can phosphorylate chicken
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gizzard MLCK and increase its phosphotransferase activity in vitro (29). In addition,
transient transfection of a mutationally activated MEKl increased both MLCK and LC20

phosphorylation in COS-7 cells, which were reversed by pretreatment with PD098059
(29).

ERK and thinfilament regulation. The present findings that[Ca ]/ and the
degree of LC20 phosphorylation decline from their peak values to lower steady-state
levels during phenylephrine-induced sustained uterine artery contraction, is in agreement

with previous results(8,12, 34, 54). Previously, the dissociation offorce and LC20

phosphorylation was postulated to he a consequence ofthe "latch" state (25, 35).

However,recent studies have suggested an additional thin filament regulation in smooth
muscle contraction(21, 33). The present study demonstrated that PD098059 increased

force development at given levels of LC20 phosphorylation mediated by phenylephrine.
This suggests that in the uterine artery ai-adrenoceptor-mediated contractions are

regulated, in addition to the thick filament pathway, by thin filament pathways. More
importantly, the present results suggest that ERK inhibits this ai-adrenoceptor-mediated
thin filament regulation of contractions. Nevertheless, PD098059 inhibited the

phenylephrine-induced contraction, suggesting that the thick filament regulatory
pathway, i.e. LC20 phosphorylation, predominates in ai-adrenoceptor-mediated uterine
artery contractions.

The idea that ERK may inhibit thin filament regulatory pathways is further

supported by the results ofPKC-mediated contractions in the uterine artery. PKC

activation ofsmooth muscle contraction has been well demonstrated from studies showing
that phorbol esters, known to activate PKC,induce slow sustained contractions in many
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types of vascular smooth muscle(7,10,23,24,40,44).In our previous studies in the uterine
artery, we showed that PDBu increased PKC activity and induced contractions(55).
Phosphorylation of LC2b has been reported in phorbol ester-induced contractions(22,41,

42,43). However,the significance of phorbol ester-induced LC20 phosphorylation in the
contraction is controversial, and there is an inconsistency in the dependence of LC20

phosphorylation on [Ca^"*"],. For instance, it has been reported that phorbol-12,13dibutyrate induces LC20 phosphorylation in Ca^'^-depleted rat aortae (22,43), but 12deoxyphorbol-13-isobutyrate does not induce LC20 phosphorylation in ferret aortae, even

in the presence of extracellular Ca^^(24). In addition, previous studies showed
dissociation between LC20 phosphorylation and tension development in response to
phorbol esters(14,31,47). The present study demonstrated that PDBu induced

contractions independent ofchanges in either [Ca^"^]/ or LC20 phosphorylation levels. This
suggests that in the uterine artery PKC-induced contraction is mediated predominately
through thin filament regulatory pathway^. Phorbol iSter-induced contractions have been

shown to involve regulatory components,including caldesmon and calponin, associated
with thin filaments(33,45,46, 53). Phosphorylation of caldesmon by PKC reverses its

inhibitory effect on myosin ATPase (48). The present finding that PD098059 enhanced

PKC-mediated contraction without changing either [Ca^"^], or LC20 phosphorylation levels
reenforces the conclusion that ERK inhibits the thin filament regulatory pathway in the
uterine artery.

In intact vascular smooth muscle,ERK has been demonstrated as a physiologically
relevant caldesmon(CaD)kinase mediating CaD phosphorylation(2,3,4,5). CaD functions
as a thin filament regulatory protein and exerts an inhibitory effect on vascular smooth
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muscle contractions(13,27,36). It has been proposed that ERK-mediated phosphorylation
ofCaD reverses the inhibitory activity of CaD on actin-actiVated myosin ATPase,hence
activating the thin filament pathway(15,17,21,33). Nonetheless,the importance of CaD

phosphorylation at ERK specific sites (particularly at Ser^^^)in smooth muscle
contraction remains controversial. Krymsky et al.(30)showed that ERK phosphorylation

of gizzard smooth muscle CaD did not reverse its inhibitory effects on myosin ATPase.

In addition, Nixon et al.(37)demonstrated that CaD phosphorylation by recombinant,

activated ERK2 had no effect on the Ca^^ sensitivity of Triton-permeabilized vascular
smooth muscle preparations, and concluded that the phosphorylation of CaD by ERK is
temporally associated with, but not involved in, force generation in smooth muscle. In

porcine carotid artery stimulated with endothelin-1, D'Angelo and Adam(8)examined
the interrelationship among ERK activity, phosphorylation of CaD and LCao, and
isometric force. They demonstrated that the inhibitory effect ofPD098059 on force could

not be correlated with a corresponding effect on ERK-mediated CaD phosphorylation

because force in arterial strips stimulated with endothelin-1 in the absence or presence of
PD098059 tended to approximate each other over time, despite significant differences in
the level of CaD phosphorylation.

In the present study, we demonstrated that PDBu produced parallel time courses

in increasing phosphorylation ofERK42/44 and CaD at Ser'^^ and the phosphorylation was
blocked by PD098059, suggesting ERK-mediated phosphorylation of Ser^^'in CaD in the
uterine artery. This is in agreement with previous findings (9). The novel finding ofthe
present study is that PD098059 had opposite effects on PDBu-induced CaD

phosphorylation at Ser'®^ and contractions. It blocked phosphorylation of CaD at Ser'^®,
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but potentiated the contractions. This suggests that ERK-dependent phosphorylation of

CaD at Ser'^^ may not be involved in the PDBu-induced contraction, but rather inhibit it
in the uterine artery. Although we were unable to determine phosphorylation of CaD at

Ser'^^ due to the lack of appropriate antibody, previous study demonstrated that the major

site of ERK-dependent phosphorylation in CaD was at Ser^^^ (9). Although all ofthe
phosphate incorporated into CaD by the ERK is in either Ser^^^ or Ser^^^, not all ofthe
phosphate in CaD is accoimted for by these two sites(3, 9). In addition to ERK-

dependent phosphorylation sites, phorbol esters and activation ofPKC may increase
phosphorylation of CaD at other sites, directly or indirectly through unknown

mechanisms(4,9,48,50, 51). Although CaD phosphorylation in vitro by PKC was at

different sites, as compared with those in PDBu-induced phosphorylation of CaD in
intact canine aortas(3), endogenous CaD kinase activity in sheep aorta smooth muscle

was purified and identified as a proteolytic fragment ofPKC(51). PKC phosphorylated

sheep aorta CaD both in native thin fil^ents and in the isolated state at multiple sites of

Ser^^^, Ser^^', Ser^®®, Ser®^^, Ser^^^ and Ser'^^. PKC-mediated phosphorylation of both
intact CaD and of its C-terminal fragment containing 658-756, significantly decreased
their ability to inhibit acto-heavy meromyosin ATPase (51). Taken together, as shown in
Fig. 7, we propose that in sheep uterine artery PKC induces phosphorylation of CaD at

Ser^^^ through activation ofERK,as well as at other site(s)through unknown
mechanisms. It is the phosphorylation of CaD at site(s) other than Ser'^^ that may be
important in reversing the inhibitory effect of CaD on myosin ATPase and leading to

contractions. Phosphorylation ofERK-dependent Ser^^^ may not lead to the reversal of

107

noQ

CaD inhibitory effects on myosin ATPase. Instead, phosphorylation of Ser

may inhibit

PKC-mediated phosphorylation ofthe other site(s).
In summary, we have shown in the pregnant uterine artery that ai-adrenoceptor-

mediated contraction is regulated through both thick and thin filament pathways, with the

thick filament regulatory pathway, i.e. LC20 phosphorylation, predominating. However,
PKC-mediated contraction is regulated predominately through thin filament pathways, i.e.

independent ofchanges in LC20 phosphorylation. ERK activation differentially regulates
thick and thin filament pathways in the uterine artery. ERK potentiates the thick filament

regulatory pathway by elevating LC20 phosphorylation via increases in [Ca^"^], and Ca^"^
sensitivity of LC20 phosphorylation. In contrast, the present study indicates that ERK

attenuates thin filament regulatory pathways, and suppresses contractions independent of

changes in LC20 phosphorylation in the uterine artery. Although it is not clear at present

whether the ERK-mediated inhibition ofthe thin filament regulatory pathway is unique to
the pregnant uterine artery, or it is a more generalized mechanism,this novel finding
suggests an intriguing hypothesis that, among ERK's effects, caldesmon phosphorylation
at ERK-specific sites may stabilize its inhibitory effect on actin-activated myosin ATPase.
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Figure 1. Effect ofPD098059 on phenylephrine-induced intracellular Ca^"^
•

2"H

concentration([Ca ]/), LC20 phosphorylation, and contraction in the uterine artery.

Arterial rings were pretreated with 30 pM PD098059 or with the vehicle DMSO (control)

for 30 min,followed by stimulation with 3 )j,M phenylephrine. [Ca^"^],,LC20
phosphorylation, and contraction were recorded simultaneously in the uterine artery.
Representative Western immunoblot shows LC20 and phosphorylated LC20(LC20-P)
induced by phenylephrine at indicated time points, fiiata are the means ± SEM from four
to nine anirnals. All values ofPD098059-treated tissues at and after 5 seconds are

significantly decreased as compared to the control, and are indicated by *(P < 0.05).

120

■ Control

120n

•+PD098059

« 100
Q.
=

(0

<0

-=■

60

O

8

40
20

100

200

300

Time (s)
0

3

10

20

30

m■

€iiP

120-,

^ O«

80-

§ 2

60-

Q- o

40-

o

O

^

O

300 s

LC20
LC20-P

1

• Control

~ 8) 100H
^ <D

60

+PD098059

..

i-v

O ^

20-

100

200

300

Time (s)
120-1

w 100-1
Q.

O 0)

■ Control
•+PD098059

80-

60I- t;
40-

100

200

Time (s)

121

300

Figure 2. Effect of PD098059 on phenylephrine-mediated LC20
•
2*4"
phosphorylation/[Ca
],• relation in the uterine artery. Arterial rings were pretreated

with 30 pM PD098059 or with the vehicle DMSO (control) for 30 min,followed by

stimulation with 3 pM phenylephrine. Increases of LC20 phosphorylation stimulated by

phenylephrine were plotted to show responses as a function of[Ca^"^]/(fura 2 signal,
Rf340/38o) at each corresponding time point(from 3 to 30 seconds). Data are the means ±
SEM from four to nine animals.
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Figure 3. Effect of PD098059 on phenylephrine-induced force/LC2o

phosphorylation relation in the uterine artery. Arterial rings were pretreated with 30
pM PD098059 or with the vehicle DMSO (control) for 30 min,followed by stimulation
viith 3 jiM phenylephrine. Increases of tension stimulated by phenylephrine were plotted
to show responses as a function of phosphorylated LC20 measured simultaneously in the
same tissue at each corresponding time point(0-10 s for the control, and 0-30 s for the

PD098059 treated, shown in Fig. 1)(panel A). Panel B shows the relation between the

levels of LC20 phosphorylation from control and PD098059-treated tissues at
corresponding tensions developed, calculated from the curves in panel A. The dash line
shows the line of identity. Data are the means ± SEM from four to nine animals.
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Figure 4. Effect of PD098059 on PDBu-stimulated tension and LC20

phosphorylation in the uterine artery. Arterial rings were pretreated with 30 pM
PD098059 or with the vehicle DMSO (control) for 30 min,followed by stimulation with
5 pM PDBu.PDBu-induced contraction and LC20 phosphorylation (LC20-P) were
measured simultaneously in the same tissues. Representative Western immunoblot shows

LC20 and no phosphorylated LC20(LC20-P)induced by PDBu at indicated time points.

Phenylephrine (PE)-induced phosphorylated LC20 is shown, and serves as a positive
control. Data are the means ± SEM from seven animals. * P < 0.05 vs control tensions.
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Figure 5. Effect of PD098059 on PDBu-stimulated phosphorylation of ERK42/44 in
the uterine artery. Arterial rings were pretreated with 30 pM PD098059 or with the

vehicle DMSO (control)for 30 min,followed by stimulation with 5 pM PDBu.PDBu-

induced increase in phosphorylated ERK42/44(p-ERK) was determined by Western
immunoblot analysis. Data are the means ± SEM from six animals.
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Figure 6. Effect of PD098059 on PDBu-stimulated phosphorylation of caldesmon

(Ser^^')in the uterine artery. Arterial rings were pretreated with 30 pM PD098059 or
with the vehicle DMSO (control) for 30 min,followed hy stimulation with 5 pM PDBu.

PDBu-induced increase in phosphorylated caldesmon at Ser^^^(p-CaDygg) was
determined by Western immunoblot analysis. Data are the means ± SEM from four to six
animals.
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Figure 7. Proposed model: ERK-dependent phosphorylation of CaD at Ser^*'
inhibits PKC-mediated contractions. We propose that PKC induces phosphorylation

of CaD at Ser^^^ through activation of ERK,as well as at other site(s) through unknown
mechanisms in sheep uterine artery. It is the phosphorylation of CaD at site(s) other than

that may^be important in reversing the inhibitory effect of CaD on myosin ATPase

and leading to contractions. Phosphorylation of ERK-dependent Ser^^^ may not lead to
the reversal of CaD inhibitory effects on myosih AXPase. Instead, phosphorylation of

Ser^^^ may inhibit PKC-mediated phosphorylation ofthe other site(s).
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CHAPTER FOUR

Adaptation of Uterine Artery Thick and Thin Filament Regulatory Pathways to
Pregnancy

DaLiao Xiao and Lubo Zhang

This chapter was submitted for publication to the American Journal ofPhysiology
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Abstract

Little is known about the adaptation of contractile mechanisms of uterine artery
smooth muscle to pregnancy. The present study tested the hypothesis that pregnancy
differentially regulates thick and thin filament regulatory pathways in the uterine artery.

Isometric tension, intracellular free Ca^^ concentration ([Ca^"^]i), and phosphorylation of
20 kDa myosin light chain(MLC20)were measured simultaneously in uterine arteries

isolated from nonpregnant and near-term (140 days gestation) pregnant sheep.

Phenylephrine-mediated [Ca^"^i, MLC20 phosphorylation and contractions were
significantly increased in pregnant, as compared with nonpregnant, uterine arteries. In

contrast, phenylephrine-mediated Ca^"^ sensitivity of MLC20 phosphorylation was
decreased in the pregnant uterine arteries. Simultaneous measurement of phenylephrinestimulated tension and MLC20 phosphorylation in the same tissue indicated a decrease in
MLC20 phosphorylation-independent contractions in the pregnant uterine arteries. In

addition, activation of protein kinase C(PKC)produced significantly lower sustained
contractions in pregnant, as compared with nonpregnant, uterine arteries in the absence

of changes in MLC20 phosphorylation levels in either vessels. In the nonpregnant uterine
arteries, the ERK inhibitor PD098059 significantly increased phenylephrine-mediated,
MLC20 phosphorylation-independent contractions. The results suggest that in the uterine

artery pregnancy upregulates ai-adrenoceptor-mediated Ca^"^ mobilization and MLC20

phosphorylation. In contrast, pregnancy downregulates the Ca^"^ sensitivity of
myofilaments, which is mediated by both thick and thin filament pathways.
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Introduction

Pregnancy is associated with a significant decrease in uterine vascular tone and a
striking increase in uterine blood flow that optimizes the delivery of oxygen and
substrates to the developing fetus via the placenta. Previous studies have focused on the
endothelial adaptation, and have shown an increase in endothelial nitric oxide
synthesis/release in the uterine artery during pregnancy(8,35,44,46). However, little is
known about the adaptation of contractile mechanisms of uterine artery smooth muscle to
pregnancy. Pregnancy causes a transient and reversible sympathetic denervation of the

uterine artery(21, 27, 28), and an increase in contractile reactivity to nonsynaptic ai-

adrenergic stimulation (3,4,11,12,30,43,47). In addition, recent studies have
demonstrated that protein kinase C(PKC)-mediated sustained contraction is

significantly attenuated in the pregnant uterine artery (47). PKC has been proposed to

play an important role in the regulation of basal vascular tone and arterial caliber, the
major determinants of blood flow (13, 26, 31).

Smooth muscle contraction is regulated through both thick and thin filament

regulatory pathways. The thick filament regulation is mediated by both Ca^"^-dependent
mechanisms that lead to activation of myosin light chain kinase(MLCK)and

phosphorylation of20-kD regulatory light chain of myosin(MLC20),and Ca^"^independent mechanisms that involve inactivation of myosin light chain phosphatase
(MLCP)and a decrease in MLC20 dephosphorylation(18,19,32). In addition to the thick
filament regulation, many studies have demonstrated dissociation between MLC20
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phosphorylation and cross-bridge cycling rates/tension development, suggesting a thin
filament regulatory pathway (5,25).
)

Our recent studies have shown in pregnant ovine uterine arteries that aiadrenoceptor-mediated contractions are regulated through both thick and thin filament
pathways, with the thick filament regulatory pathway, i.e., MLC20 phosphorylation,
predominating (45). In contrast, activation ofPKC induced contractions without changes

in MLC20 phosphorylation levels(45). These studies have also shown that extracellular

signal-regulated kinase(ERK)modulates contractile force in the pregnant uterine artery
by a dual regulation ofthick and thin filament pathways. ERK potentiated aiadrenoceptor-stimulated MLC20 phosphorylation via increases in intracellular free

concentrations([Ca^"^i) and the Ca^^ sensitivity of MLC20 phosphorylation. In contrast,
ERK attenuated the thin filament regulatory pathway by suppressing the contractions
independent ofchanges in MLC20 phosphorylation levels.

In the present study, we tested the hypothesis that pregnancy differentially
regulates thick and thin filament regulatory pathways in the uterine artery. Isometric
•

^I

tension,[Ca ]i and MLC20 phosphorylation levels were measured simultaneously in

uterine arteries isolated from nonpregnant and near-term (140 days gestation) pregnant
sheep. The present study provides evidence that pregnancy upregulates ai-adrenoceptor-

mediated intracellular Ca^^ mobilization and MLC20 phosphorylation, but downregulates
* * *
the Ca2~f" sensitivity
of MLC20 phosphorylation. In addition, pregnancy significantly

downregulates MLC20 phosphorylation-independent contractions in the uterine artery.
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Methods

Tissue preparation. Nbnpregnant and pregnant(-140 days gestation) sheep were
anesthetized with thiamylal(10 mg/kg)administered via the external left jugular vein.
The ewes were then intubated, and anesthesia was maintained on 1.5% to 2.0% halothane

in O2 throughout the surgery. An incision in the abdomen was made and the uterus
exposed. The uterine arteries were isolated and removed without stretching, and were

placed into a modified Krebs solution(pH 7.4)ofthe following composition (in mM):
115.2NaCl,4.7 KCl, 1.80 CaCk, 1.16MgS04,1.I8KH2PO4,22.14NaHCOs,0.03
EDTA,and 7.88 dextrose. The Krebs solution was oxygenated with a mixture of95% O25% CO2. After the tissues were removed, animals were killed vdth euthanasia solution

(T-61, Hoechst-Roussel; Somervile, NJ). All procedures and protocols used in the present
study were approved by the Animal Research Committee of Loma Linda University, and

followed the guidelines in the National Institutes of Health Guidefor the Care and Use of
Laboratory Animals.
\

Contraction studies. The third (nonpregnant) and fourth (pregnant) branches of

the main uterine arteries with a similar external diameter were separated from the
surrounding tissue, and were cut into 2-mm ring segments. Isometric tension was

measured in the Krebs' solution in tissue bath at 37 °C,as described previously (45).

After 60 min ofequilibration, each ring was stretched to the optimal resting tension as
determined by the tension developed in response to 120 mM KCl added at each stretch

level. Tissues were then stimulated with phenylephrine or phorbol 12,13-dibutyrate

(PDBu)(Sigma, St. Louis, MO),and contractile tensions and MLC20 phosphorylation
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levels were measured simultaneously in the same tissues. Tensions developed were
continuously recorded with an on-line computer. To measure phosphorylated MLC20
simultaneously in the same tissue, arterial rings were snap-frozen with liquid N2-cooled
clamps at the indicated times, and rapidly immersed in a dry ice-acetone slurry containing
10% trichloroacetic acid(TCA)and 10 mM DTT mixture. Tissues were then stored at -

80°C until the analysis of MLC20 phosphorylated. In certain experiments, tissues were

pretreated with PD098059(30 pM)(Sigma, St. Louis, MO)or vehicle(DMSG)for 30
min,followed by stimulation with phenylephrine.

Measurements ofMLC20phosphorylated. Tissue MLC20 phosphorylated levels

were measured as described previously(45). Briefly, tissues were brought to room
temperature in a dry ice-acetone-TCA-DTT mixture and washed three times with ether to

remove the TCA. Tissues were then extracted in 100 pL of sample buffer containing 20
mM Tris base and 23 mM glycine(pH 8.6), 8.0 M urea, 10 mM DTT,10% glycerol and

0.04% bromophenol blue, as previously described. Sample(20 pi) were electrophoresed
at 12 mA for 2.5 h after a 30 min pre-run in 1.0 mm mini-polyacrylamide gels containing

10% arcelamide-0.27% bisacrylamide,40% glycerol and 20 mM Tris Base(pH 8.8).
Proteins were transferred to nitrocellulose membranes and subjected to immunoblot with
a specific MLC20 antibody (1:500, Sigma, St. Louis, MO). Goat anti-mouse IgG

conjugated with horseradish peroxidase was used as a secondary antibody(1:2000,

Calbiochem). Bands were detected with enhanced chemiluminescence(ECL), visualized
on films and were analyzed with the Kodak ID image analysis software. Moles of
phosphate per mole of myosin light chain (fractional MLC20 phosphorylated) were

calculated by dividing the density ofthe pihosphorylated band by the sum ofthe densities
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ofthe phosphorylated plus the unphosphorylated bands. In some experiments,

phosphorylated MLC20 was corrected for protein content differences between
/

nonpregnant and pregnant uterine arteries, and was expressed as mg MLC20
phosphorylated/g tissue wet weight, as previously described in ovine uterine arteries by
Annibale et al.(4).

Simultaneous measurement of

and tension. Simultaneous recordings of

contraction and [Ca^"^]i in the same tissue were conducted as described previously(49).
Briefly, the arterial ring was attached to an isometric force transducer in a 5-ml tissue

bath mounted on a CAF-110 intracellular Ca^^ analyzer(model CAF-110, Jasco; Tokyo,
Japan). The tissue was equilibrated in Krebs buffer under a resting tension of 0.5 g for 40

min. The ring was then loaded with 5 pM fura 2-AM (Molecular Probes, Eugene, OR)for

3 b in the presence of0.02% Cremopbor EL at room temperature(25 °C). After loading,
the tissue was washed with Krebs solution at 37°C for 30 min to allow for hydrolysis of
fura 2 ester groups by endogenous esterase. Contractile tension and fura 2 fluorescence
were measured simultaneously at 37°C in the same tissue. The tissue was illuminated

altematively(125 Hz)at excitation wavelengths of340 and 380 nm,respectively, by
means oftwo monocbromators in the light path of a 75-w xenon lamp. Fluorescence
emission from the tissue was measured at 510 nm by a pbotomultiplier tube. The

fluorescence intensity at each excitation wavelength (F340 and F380, respectively) and the
ratio ofthese two fluorescence values (Rc40/38o) were recorded with a time constant of
250 ms and stored with the force signal on a computer.
Data analysis. Data were analyzed by computer-assisted linear or nonlinear
regression to fit the data using GraphPad Prism(GraphPad software; San Diego, CA).
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Results were expressed as means ± SEM. Differences were evaluated for statistical
significance(P < 0.05)by one-way ANOVA and Student's Mest.

141

Results

Phenylephnne-induced

and tension. Phenylephrine produced dose-

dependent increases in [Ca^"^]i and contractions in both nonpregnant and pregnant uterine
arteries (Fig. 1). As shown in Fig.lA, the phenylephrine-induced concentrationcontraction curve was shifted to the left in the pregnant uterine artery(pD2: 5.86 + 0.13),
as compared with that in the nonpregnant uterine artery(pDi; 5.15 ± 0.18)(P < 0.05).

The maximal responses were 2.51 ± 0.14 g and 1.79 ± 0.19 g in the pregnant and

nonpregnant uterine arteries, respectively(P < 0.05). In accordance, phenylephrine

produced a dose-dependent increase in [Ca^"*"]!(fura-2, Rc4o/38o) in both nonpregnant
(pDa: 5.6 ± 0.14) and pregnant(pDi; 6.0 ± 0.12) uterine arteries(P = 0.07)(Fig. IB). The
maximal response was significantly increased in the pregnant(0.103 ± 0.009), as
compared with that in the nonpregnant(0.032 ± 0.004) uterine arteries(P < 0.05).
Phenylephrine-induced MLC20phosphdiylation. Fig. 2 shows the time courses

of phenylephrine-induced increases in phosphorylated MLC20in nonpregnant and
pregnant uterine arteries. As shown in Fig. 2,the initial rate of phenylephrine-stimulated

MLC20 phosphorylation(MLC20-P mg/g wet wt/sec) and the peak phosphorylation levels
(MLC20-P mg/g wet wt) were significantly increased in pregnant uterine arteries(the rate:

0.071 ± 0.017; the peak level: 0.881 ± 0.056), as compared with those in the nonpregnant
vessels (the rate: 0.022 ± 0.004; the peak level: 0-629 ± 0.061)(P < 0.05). As shown in

Fig. 3, phenylephrine-induced dose-dependent increases in phosphorylated MLC20 were
significantly increased in pregnant, as compared with nonpregnant, uterine arteries.
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MLC20phosphorylation-[Ca^^]i relation. Regulatory pathways in smooth
muscle that modulate the Ca^"^ dependence offorce may exert their effects by altering the
dependence of MLC20 phosphorylation on[Ca ]i, or the dependence offorce on MLC20
9+

phosphorylation. To determine the effect of pregnancy on the regulation ofthe Ca
9-t-

sensitivity of MLC20 phosphorylation at given [Ca ]i, we examined the relation of

phenylephrine-induced dose-dependent increases in [Ca^"^]i and phosphorylated MLC20 in
both nonpregnant and pregnant uterine arteries. As shown in Fig. 4,there was a

significant decrease in the slope (MLC2o-P/[Ca^"^]i)in pregnant arteries(7.7 ± 2.2), as
compared with that in nonpregnant vessels(20.7 ± 7.6)(P < 0.05).
Force-MLC2o phosphorylation relation. To further examine whether

pregnancy regulated contractions independent ofchanges in MLC20 phosphorylation, we
measured the phosphorylated MLC20 and contractions simultaneously in the same tissues

stimulated with different doses of phenylephrine. Phenylephrine-induced tensions were

plotted against their corresponding phosphorylated MLC20 levels in both nonpregnant and
pregnant tissues. As shown in Fig. 5,there was a significant rightward shift in the
tension-MLC2o phosphorylation relation curve in the pregnant, as compared with
nonpregnant, uterine arteries. The slopes obtained were not different between
nonpregnant and pregnant uterine arteries.

Effect ofPD098059 on phenylephrine-induced MLC20phosphorylation and
contractions. Our previous studies demonstrated that the ERK inhibitor, PD098059,

significantly inhibited phenylephrine-induced increases in MLC20 phosphorylation and
contractions, but increased MLC20 phosphorylation-independent contractions in pregnant
ovine uterine arteries (45). To determine whether PD098059 had similar effects in the
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nonpregnant uterine arteries, we examined the effect ofPD098059 on phenylephrineinduced increases in phosphorylated MLC20 and contractions in nonpregnant uterine
arteries. As shown in Fig. 6,PD098059 inhibited the initial increases in MLC20

phosphorylation and tension development induced by phenylephrine, but significantly
enhanced the contractions independent of changes in phosphorylated MLC20 by

increasing the slope(tension/MLC2o-P)from 6.8 ± 1.7 to 12.6 ± 1.1 (P < 0.05)(Fig. 6C).
PDBu-stimulated MLC20phosphorylation and tension. We previously

demonstrated that PDBu-induced contractions were significantly decreased in pregnant,
as compared with nonpregnant, uterine arteries (47). To determine the mechanism of
MLG20 phosphorylation in PDBu-mediated contractions, we measured PDBu-induced

contractile tensions and phosphorylated MLC20 levels simultaneously in the same tissues
of nonpregnant and pregnant uterine arteries. As shown in Fig. 7,PDBu produced a

significantly decreased contraction in pregnant, as compared with nonpregnant, uterine
arteries, in the absence of changes in phosphorylated MLC20 levels in either vessels.
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Discussion

The present study offers the following new findings. First, ai-adrenoceptormediated Ca mobilization and MLC20 phosphorylation are significantly greater in

pregnant than nonpregnant uterine arteries. Second, ai-adrenoceptor-mediated Ca^^
sensitivity of MLC20 phosphorylation, and MLC20 phosphorylation-independent
contractions are significantly less in pregnant than nonpregnant uterine arteries. Third,

activation ofPKC induces contractions in the absence ofchanges in MLC20

phosphorylation in both nonpregnant and pregnant uterine arteries, and pregnancy is
associated with a decrease in MLC20 phosphorylation-independent contractions in the

uterine artery. Fourth, in agreement with the finding in the pregnant uterine artery(45),

the ERK inhibitor PD098059 decreases ai-adrenoceptor-mediated initial rising in MLC20
phosphorylation and contractions, but increases the MLC20 phosphorylation-independent
contractions in the nonpregnant uterine arteries.

The present finding that ai-adrenoceptor-mediated contractions ofisolated

uterine arteries were increased in the pregnant animals is in agreement with previous
studies(3,4,11,12, 30,43,47). This is probably due in part to a transient and reversible
sympathetic denervation ofthe uterine artery during pregnancy (21, 27, 28), resulting in
a sensitization of postsynaptic ai-adrenoceptor-mediated responses. In contrast,
pregnancy did not result in changes in postsynaptic ai-adrenoceptor-mediated
contractions in systemic vessels(3,17). In addition, 5-HT- and KCl-stimulated

contractions were the same between nonpregnant and pregnant uterine arteries (48).
These findings suggest a specific effect of pregnancy on ai-adrenoceptors in the uterine
artery, and are consistent with the notion of sympathetic denervation-mediated
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sensitization of postsynaptic ai-adrenoceptor-mediated responses. Previous studies
demonstrated that the increased ai-adrenoceptor-mediated contractions in pregnant
ovine uterine arteries were not the result of increased cellularity in the arterial cross
\

section, but rather were related to properties of the vascular smooth muscle themselves
(4). In addition, uterine arterial wall thickness and actin-to-myosin ratio were found
unaltered during pregnancy (4).

Consistent with the sensitization of postsynaptic ai-adrenoceptor-mediated

Ca^"^ mobilization and contractions, we have demonstrated that the density of aiadrenoceptors and norepinephrine binding affinity to ai-adrenoceptors are significantly

increased in pregnant, as compared with nonpregnant, ovine uterine arteries, resulting in
increased inositol 1,4,5-trisphosphate (IP3)synthesis(42,43). The role ofIP3 as the

messenger ofagonist-mediated Ca^"^ mobilization in smooth muscle has been firmly
established(36). In addition to the possible sensitization of postsynaptic ai-adrenoceptors
due to sympathetic denervation in the pregnant uterine artery, pregnancy and steroid

hormones may also have direct effects on ai-adrenoceptor-mediated responses in the
uterine artery. In isolated female rat aorta, estrogen pretreatment increased the number

of ai-adrenoceptors and the amount ofintracellular Ca^"^ available for contraction (6). In
myometrial smooth muscle, progesterone had no effect on IP3-dependent or -independent

Ca^^ release from intracellular Ca^"^ stores(15), but significantly increased aiadrenoceptor-mediated synthesis of inositol phosphates (33).
The increased Ca mobilization is likely to play an important role in the

increased MLC20 phosphorylation by activation of ai-adrenoceptors in the pregnant
uterine artery in the present study. This is consistent with the previous finding in ovine
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uterine arteries that phenylephrine-stimulated total amount of MLC20 phosphorylated
was increased in pregnant as compared with nonpregnant vessels (4). In contrast,
studies in human myometrial smooth muscle demonstrated that KCl-mediated MLC20

phosphorylation was significantly reduced in pregnant as compared with nonpregnant
tissues (41). This further suggests that increased MLC20 phosphorylation observed in
the pregnant uterine artery is specific to ai-adrenoceptor-mediated pathway. As

discussed above,this selective sensitization occurred in the upstream of signal

transduction pathway at the receptor levels, i.e. ai-adrenoceptor density and
endogenous agonist binding affinity. Unlike ai-adrenoceptors, KCl-mediated MLC20

phosphorylation depends on Ca^^ influx through voltage-sensitive Ca^^ channels. Both
estrogen and progesterone have been demonstrated to inhibit Ca^"^ influx in smooth
muscle(15, 34).

In addition to intracellular Ca^^ concentrations, phosphorylation of MLC20 is also
regulated by activities of MLCK and MLCP. Although it is unknown at present whether
MLCK activity is altered in the uterine artery during pregnancy, the specific activity of
MLCK was not different between nonpregnant and pregnant myometrium (41). In the

present study, we have demonstrated that pregnancy is associated with a significant

decrease in the Ca^^ sensitivity of MLC20 phosphorylation in response to phenylephrine,
i.e. less MLC20 phosphorylation at given [Ca^^Ji in the pregnant uterine artery, suggesting
an increase in MLCP activity in the pregnant vessels. It has been demonstrated that

steroid hormones regulate the expression of MLCP catalytic(PPl-5)and large regulatory
subunit(MYPT),and increase the levels ofPPl-5 and MYPT in pregnant myometrium
(39). In addition, estrogen and progesterone treatment inhibited agonist- and GTPyS-
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induced Ca^"^ sensitization of smooth muscle by increasing the expression of Rndl and
Rnd3, which inhibited the RhoA-dependent pathways(9,24).
The present finding that ai-adrenoceptor-mediated contractions at given levels
of MLC20 phosphorylation were significantly deceased in pregnant as compared with
nonpregnant uterine arteries suggests that pregnancy enhances the thin filament-mediated

inhibition of contractions in the uterine artery. This is further supported by the results of
PKC-mediated contractions in the uterine artery. In the present study, we have
demonstrated that PKC-induced contractions are independent of changes in MLC20

phosphorylation in both nonpregnant and pregnant uterine arteries, indicating that in the
uterine artery PKC-induced contractions were mediated predominately through thin filament

regulatory pathways. Although many studies have demonstrated that PKC mediates Ca^"^-

independent contractions by increasing myofilament Ca^"^ sensitivity in vascular smooth
muscle, the significance of MLC20 phosphorylation in PKC-induced contractions remmns

controversial, and may be tissue-dependent. Consistent with the present finding, the

dissociation between MLC20 phosphorylation and tension development in response to
phorbol esters has been demonstrated previously(16, 37). In addition to the thick

filament regulation, i.e. MLC20 phosphorylation,through MLCP,the Ca^"^ sensitivity of
myofilaments is also regulated through smooth muscle thin filament actin-binding

proteins such as caldesmon that inhibits myosin ATPase activity. Studies using the

antagonist peptide GS17C and the antisense have strongly suggested an important and
physiologically relevant role for caldesmon in suppressing smooth muscle tone (25). It
has been demonstrated that PKC induces phosphorylation ofcaldesmon, which reverses its
inhibitory effect on myosin ATPase(38,40,45). The finding that PKC-mediated
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contractions were attenuated in the pregnant uterine artery in the present study further

suggests an adaptation ofthe thin filament regulatory pathway to pregnancy. Indeed, it
has been reported that caldesmon levels increase in both human and rat myometrixim

during pregnancy, which contributes to a suppression of contractility ofthe pregnant
myometrium (23,41).

In agreement with our previous findings in the pregnant uterine artery, the

present study has demonstrated that the ERK inhibitor PD098059 causes a significant

leftward shift in the force-MLC2o phosphorylation relation in the nonpregnant uterine
artery. This suggests that ERK plays a key role in maintaining the thin filament-mediated

inhibitory effect on contractions ofthe uterine artery. We have previously demonstrated
that pregnancy selectively enhances the role ofERK in ai-adrenoceptor-mediated

contractions and its effect in suppressing PKC-mediated contractions in the uterine artery
(47). In vascular smooth muscle,ERK has been demonstrated as a physiologically relevant

caldesmon kinase, and phosphorylates caldesmon at Ser^^^(1,2). However,whether
caldesmon phosphorylation at ERK specific sites induces smooth muscle contraction'

remains controversial(10,22,29). Our recent studies in the pregnant uterine artery have

suggested that ERK-mediated phosphorylation of caldesmon may stabilize the inhibitory
effect of caldesmon on actin-activated myosin ATPase (45). Given that pregnancy

significantly increases ERK protein levels and signaling pathway in the uterine artery(7,
14,47), ERK is likely to play an important role in the adaptation of uterine artery
contractility to pregnancy by increasing the thin filament-mediated inhibitory effect on
contractions ofthe uterine artery.
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In the perspective of physiology, during pregnancy the uterine vasculature acts as
a low-resistance shunt to accommodate the large increase in uteroplacental blood flow

required for normal fetal development. In addition to increased endothelial nitric oxide
synthesis/release, pregnancy is associated with a transient and reversible sympathetic
denervation ofthe uterus and uterine artery, which is associated with a profound decrease in
contractions ofsmooth muscle to electric field stimulation(21,28). Although the decreased
sympathetic innervation,combined with increased nitric oxide release, maintain low uterine

vascular tone in pregnancy, sympathetic denervation is likely to sensitize postsynaptic aadrenergic pathway, and to increase ability of nonsynaptic a-adrenergic-mediated
contractions in the uterine artery. This may be important for the mother to protect herself

under stresses, and allow a redistribution of blood by contracting the uterine artery to

circulating catecholamines. This is achieved in part by enhanced intracellular Ca^"^
mobilization through activation of ai-adrenoceptors resulting in activation of myosin
light chain kinase and phosphorylation of MLC20. On the other hand,the decreased Ca^^
sensitivity of myofilaments contributes to maintaining low basal vascular tone ofthe

uterine artery during pregnancy, and helps to maintain low vascular tone in response to
increased blood flow through the uterine artery during pregnancy. The cell and molecular

mechanisms involving both thick and thin filament regulatory pathways in the adaptation

of uterine artery myofilament Ca^^ sensitivity to pregnancy present important avenues for
future investigation.
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Figure 1. Phenylephrine-induced intracellular free Ca^^ concentrations ([Ca^^]i)
and contractions in the uterine artery. Cumulative concentration-response curves of

phenylephrine-induced increases in [Ca^^Ji and contractions were measured
simultaneously in the same tissues of uterine arteries obtained from nonpregnant and

pregnant ovine. Data are means ± SEM oftissues from 4 animals. The values of pDi and
the maximal response were presented in the text.
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Figure 2. Phenylephrine-induced time courses of MLC20 phosphorylation in the

uterine artery. Arterial rings of nonpregnant(NP)and pregnant(?)uterine arteries were

stimulated with 3 pM phenylephrine. Phosphorylation of MLC20 was detected by
Western immunoblot as described in the Methods. Representative immunoblot shows

unphosphorylated MLC20 and phosphorylated MLC20(MLC20-P)induced by

phenylephrine at 0-300 s. The levels of phosphorylated MLC20 were expressed as mg
phosphorylated MLC20 per g tissue wet weight. Data are means ± SEM oftissues from 4
animals.
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Figure 3. Phenylephrine-induced dose-dependent increases in MLC20

phosphorylation in the uterine artery. Arterial rings of nonpregnant and pregnant

uterine arteries were stimulated with increasing doses of phenylephrine. Phosphorylation
of MLC20 was detected by Western immunoblot as described in the Methods, and was

expressed as mg phosphorylated MLC20 per g tissue wet weight. Data are means ± SEM
oftissues from 4 animals. * P < 0.05, pregnant vj'. nonpregnant.

165

o^
OS

00

o

CO

CD

O)

0)

O

O

H

Ol

H

H

*

*

O

Oi

CD

T3

*

CD

3 CQ

CD

13

5?
CD 13

CQ

ID

MLC20-P (mg/g wet wt)

Figure 4. Phenylephrine-induced MLC20 phosphorylation-[Ca^^]i relation in the
uterine artery. Arterial rings of nonpregnant and pregnant uterine arteries were

stimulated with increasing doses of phenylephrine (0.3 to 30 pM). Increased levels of

phosphorylated MLC20 stimulated by phenylephrine were plotted to show responses as a

function of[Ca^^Ji (fura-2 signal, Rf340/38o) at each corresponding concentrations. Data are
means ± SEM of tissues from 4 animals.
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Figure 5. Phenylephrine-induced force-MLCio phosphorylation relation in the
uterine artery. Arterial rings of nonpregnant and pregnant uterine arteries were

stimulated with increasing doses of phenylephrine (0.3 to 30 pM). Increased tension
stimulated by phenylephrine was plotted to show responses as a function of

phosphorylated MLC20 measured simultaneously in the same tissue at each corresponding
concentrations. Data are means ± SEM of tissues from 4 animals.
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Figure 6. Effect of PD098059 on phenylephrine-induced contractions and MLC20
phosphorylation in the nonprcgnant uterine artery. Arterial rings were pretreated

with 30 pM PD098059 or with the vehicle DMSO (control)for 30 min,followed by
stimulation with 3 pM phenylephrine. Contractions(panel A)and MLC20

phosphorylation (panel B)were measured simultaneously in the uterine artery. Increased
tension stimulated by phenylephrine was plotted to show responses as a function of

phosphorylated MLC20 measured simultaneously iii the same tissue at each corresponding
time point(panel C). Data are means ± SEM oftissues from 5 animals.
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Figure 7. PDBu-induced contractions and MLC20 phosphorylation in the uterine
artery. Arterial rings of nonpregnant and pregnant uterine arteries were stimulated with

5 pM PDBu. PDBu-induced eontractions and MLC20 phosphorylation were measured
simultaneously in the same tissues. Data are the means ± SEM of tissues from 4 to 8

animals. * P < 0.05, pregnant v.s. nonpregnant.
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CHAPTER FIVE

ai-Adrenoceptor-Mediated Phosphorylation of MYPTl and CPI-17 in the
Uterine Artery: Role of ERK/PKC

DaLiao Xiao and Lubo Zhang

This chapter will be submitted for publication to the American Joumal ofPhysiology
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Abstract

We have previously demonstrated that ERK/PKC signaling pathways play a key
role in the regulation of Ca sensitivity and contractility ofthe uterine artery. The

present study tested the hypothesis that ERK and PKC differentially regulated myosin
light chain phosphatase activity by phosphorylation of MYPTl and CPI-17. Agonist-

induced contractions and phosphorylation of MYPTl/Thr^^®, MYPTl/Thr^^", and CPIOQ

17/Thr were measured simultaneously in the same tissues of isolated near-term

pregnant ovine uterine arteries. Phenylephrine produced time-dependent concurrent

increases in the phosphorylation of ERIC44/42 and MYPT1/Thr^^°, which preceded
contractions. In addition, phenylephrine induced phosphorylation of CPI-17/Thr^^ that
was concurrent with the contractions. In contrast, phenylephrine did not induce

phosphorylation of MYPTl/Thr^^® in the uterine artery. PD098059 inhibited
phosphorylation ofERK44/42and the initial peak phosphorylation of MYPTl/Thr^^®, but

did not affect CPI-17/Thr^^ phosphorylation. Activation ofPKC by PDBu induced a
time-dependent phosphorylation of CPI-17/Thr^^ that preceded the contractions ofthe
uterine artery. In addition, PDBu activated PKCa,and induced a co-immunoprecipitation

ofPKCa with caldesmon. The results suggest that phosphorylation of MYPTl/Thr®^® and
CPI-17/Thr play important roles in the regulation of agonist-mediated Ca sensitivity
in the uterine artery, which are regulated in part by ERK and PKC,respectively. In

addition, phosphorylated CPI-17 may regulate the Ca^"^ sensitivity by interacting with
caldesmon and reversing its inhibitory effect on myosin ATPase.
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Introduction

Smooth muscle contraction is predominantly regulated by phosphorylation of
myosin light chain, which is determined by the activities of myosin light chain kinase
(MLCK)and myosin light chain phosphatase(MLCP)(15,19). Increases in intracellular
concentrations activate MLCK resulting in phosphorylation of20 kDa myosin light

chain(MLC20)and contractions. However,the force development of smooth muscle is
9+

9+

not simply determined by intracellular Ca concentrations(21, 35,41, 58). Ca

sensitivity of myofilaments also plays an important role in the regulation ofsmooth muscle
9+

contraction. Regulation of Ca sensitivity may include at least two components,thick

filament regulation (i.e. Ca^^ sensitivity of MLC20 phosphorylation) and thin filament
regulation (i.e. MLC2ophosphorylation-independent contractions). MLCP plays a key

role in regulating Ca^"^ sensitivity of MLC20 phosphorylation (13,27, 28,46). MLCP
consists ofthree subunits: a 110 to 130 kDa regulatory subunit(MYPTl),an -37 kDa
catalytic subunit(PPlc), and a 20 kDa subimit of unknown function. Inhibition of

MLCP is regulated by at least three mechanisms: a. phosphorylation of MYPTl, b.
arachidonic acid-induced dissociation ofthe holoenzyme, and c. PKC-mediated

phosphorylation of CPI-17 at Thr^^, which becomes a potent inhibitor ofPPlc. Two

phosphorylation sites of MYPTl have been identified at Thr^^^ and Thr^^".

In addition to the thick filament regulation, Ca^"^ sensitivity is also regulated by
the smooth muscle actin-binding protein caldesmon that inhibits myosin ATPase
activity (34). Studies using the antagonist peptide GS17C and the antisense have
strongly suggested an important and physiologically relevant role for caldesmon in
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suppressing smooth muscle tone (7, 23, 36, 39). Removal of caldesmon-mediated
inhibition can be achieved by phosphorylation of caldesmon and/or a binding of other

regulatory proteins, e.g. Ca^Vcalmodulin, which reverse its inhibitory effect on myosin
ATPase.

Recently, we have demonstrated in the pregnant uterine artery that ai-

adrenoceptor-mediated contractions are regulated through both thick and thin filament
pathways, with the thick filament regulatory pathway, i.e. MLC20 phosphorylation,

predominating. However,PKC-mediated contractions were regulated predominately
through the thin filament pathway, i.e. independent of changes in MLC20 phosphorylation
(55). We have demonstrated that ERK plays an important role in the regulation of ai-

adrenoceptor-mediated contractions ofthe uterine artery (55,56). Inhibition ofERK by

PD098059 significantly decreased the Ca^^ sensitivity of MLC20 phosphorylation in
response to phenylephrine, i.e., less MLC20phosphorylation at a given intracellular Ca^^
concentration (55). However,ERK-mediated phosphorylation ofthe thin filament

binding protein caldesmon at Ser'^^ may not lead to the reversal of caldesmon inhibitory
effects on actin-activated myosin ATPase in pregnant ovine uterine arteries. In contrast,
our previous studies have suggested that in the pregnant uterine artery PKC^induced,thin
filament-dependent contractions may be mediated by a direct phosphorylation of

caldesmon or by phosphorylation of other regulatory protein(s)that may interact with
caldesmon.

In the present study, we determined the temporal relationships between

phosphorylation of MYPTl/Thr^^^, MYPT1/Thr^^°, and CPI-17/Thr^^ and contractions
induced by phenylephrine, and tested the hypothesis that ERK played a role in inhibition
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of MLCP in the uterine artery. Given that CPI-17 is a PKC substrate (8)and

phosphorylated CPI-17 may serve as a regulatory binding protein, the present study also
determined the temporal relationship between PKC-mediated phosphorylation of CPI-17
and contractions. In addition, we determined the potential direct interaction between PKC
and caldesmon by examining the co-immunoprecipitation ofPKCa isozyme with
caldesmon in the uterine artery.
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Methods

Tissue preparation. Near-term pregnant(-140 days gestation) sheep were
anesthetized with thiamylal(10 mg/kg)administered via the external left jugular vein.
The ewes were then intubated, and anesthesia was maintained on 1.5% to 2.0% halothane

in O2 throughout the surgery. An incision in the abdomen was made and the uterus

exposed. The uterine arteries were isolated and removed without stretching and placed

into a modified Krebs solution(pH 7.4) ofthe following composition (in mM): 115.21
NaCl,4.7 KCl, 1.80 CaCk, 1.16 MgS04, 1.18 KH2PO4, 22.14 NaHCOg, 0.03 EDTA,

and 7.88 dextrose. The Krebs solution was oxygenated with a mixture of95% 02-5%

CO2. After the tissues were removed, animals were killed with euthanasia solution (T-61,

Hoechst-Roussel; Somervile, NJ). All procedures and protocols used in the present study
were approved by the Animal Research Committee of Loma Linda University and

followed the guidelines in the National Institutes of Health Guidefor the Care and Use of
Laboratory Animals.
Contraction Studies. Fourth branches ofthe main uterine arteries were

separated from the surrounding tissue, and cut into 2-mm ring segments. The arterial
rings were attached to an isometric force transducer and bathed in tfie Krebs' solution
under 95% 02-5%C02 at 37 °C. Isometric tensions were measured as described

previously (56). After 60-min of equilibration in the tissue bath, each ring was stretched

to the optimal resting tension as determined by the tension developed in response to 120
mM KCl added at each stretch level. Tissues were then stimulated with phenylephrine
and/or phorbol 12,13-dibutyrate(PDBu). Tension developed was recorded with an online
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computer. At the indicated times, arterial rings were snap-frozen with liquid N2-cooled
clamps,followed by immersion in a dry ice-acetone slurry containing 10% trichloroacetic
acid(TCA)and 10 mM DTT. The rings were stored at -80°C until analysis. In certain

experiments,tissues were pretreated with PD098059(30 pM)or the vehicle(DMSO)for
30 min,followed by stimulation with phenylephrine.
Western immunoblotting analysis. Tissues were homogenized in a lysis buffer
containing 150 mM NaCl,50 mM Tris HCl, 10 mM EDTA,0.1% Tween 20,0.1% p-

mercaptoethanol, 0.1 mM phenylmethylsulfonyl fluoride, 5 pg/ml leupeptin, and 5 pg/ml

aprotinin,PH 7.4. Homogenates were then centrifugation at 4 °C for 5 min at 6,000 g and
the supematants were collected. Protein was quantified in the supernatant by the method

of Bradford (1976). Samples with equal protein were loaded on 7.5%(MYPTl/Thr®^^ and

MYPTl/Thr®^")or 10%(CPl-17/Thr^^ and P-ERK42/44) polyacrylamide gel with 0.1%
sodium dodecyl sulfate(SDS),and were separated by electrophoresis at 100 V for 2 h.
Proteins were then transferred on to nitrocellulose membrane. Nonspecific binding sites
in the membranes were blocked by an overnight incubation at 4 °G in a Tris-buffered
saline solution(TBS)containing 5% dry milk. The membranes were incubated with

primary antibodies and then with secondary antibodies. Proteins were visualized with

enhanced chemiluminescence reagents, and the blots were exposed to Hyperfilm. Results
were quantified with the Kodak electrophoresis documentation and analysis system and
Kodak ID image analysis software.

Measurement ofPKCa translocation. Uterine arteries were mounted in tissue

baths and equilibrated for at least 60 min in the Krebs' solution under 95% 02-5%C02 at
37 °C. The rings were then exposed to PDBu(3 pM)or the vehicle(DMSO)for 30 min.
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The uterine artery rings were snap-frozen and homogenized in ice-cold homogenization
buffer containing Tris-HCl 20 mM,sucrose 250 mM,EDTA 5 mM,EGTA 5 mM,PMSF
1 mM,p-mercaptoethanol 10 mM,and benzamide 1 mM.The homogenate was
centrifuged at 100,000g for 60 minutes at 4 °C,and the supernatant was used as the
cytosolic fraction. The pellet corresponding to the membrane particulate fraction was

solubilized in a buffer containing Triton X-100 at a final concentration of0.1% by

stirring on ice for 45 minutes at 4 °C,followed by centrifugation at 100,000g for 60
minutes at 4 °C to remove insoluble membrane particles. The supernatant was collected
and was referred to as the membrane particulate fraction. Immrmoreactive bands for

PKCa in cytosolic and particulate fractions were determined by Western blotting using
PKCa antibody(1;500; Santa Cruz)as described above.
Immunocytochemistry. Smooth muscle cells were freshly isolated from the

uterine arteries using a collagenase-elastase digestion mixture with gentle shaking as
described previously (43). After enzyme incubation, tissues were rinsed with the Hanks

solution, and dissociated cells were placed over im-siliconized coverslips. The cells were

settled by gravity and spontaneously adhered to the glass. Irmmmocytochemical staining

ofPKCa in freshly isolated cells was determined as previous described (24). Briefly,
after treatment, freshly isolated cells were fixed with 4% paraformaldehyde in

phosphate-buffered saline(pH 7.4). The excess fixative was quenched with 0.1% mM

glycine in 1% Bovine serum albumin(BSA)-Hanks solution. The cells were then
permeabilized with 0.1% Triton X-100 in 1% BSA-Hanks and washed in 1% BSAHanks. Cells were blocked with 10% bovine serum in 1% BSA-Hanks,reacted with the

PKCa antibody, washed in 1% BSA-Hanks with 0.05% Triton X-100,labeled with a
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secondary antibody conjugMed with FITC. Cells were then washed in 1% BSA-Hanks to
remove excess label. The cell nuclei were stained with Hoechest 33258. Cells were then

examined using a fluorescent microscope with the SPOT digital camera.

^ Co-immunoprecipitation. Co-immunoprecipitation ofPKCa and caldesmon
was determined as described previously (33). Tissues were homogenized in a buffer
containing 50 mM Tris, pH 7.4, 10% glycerol, 5 mM EGTA, 140 mM NaCl, 1% Triton,

and the protease inhibitors leupeptin and pepstatin (5.5 pM), aprotinin 20 kallikreininactivating unit, 1 mMNa3V04,10 mM NaF,0.25%(w/v)sodium deoxycholate, 100
pM ZnCl2, 20 mM P-glycerophosphate, and 2 pM PMSF. After centrifugation, the

protein concentration was determined using the Bradford method (BioRad). An equal
amoimt of protein was incubated with the caldesmon antibody overnight at 4 °C with
gentle rotation. Then, protein A/G PLUS-agarose (Santa Cruz) was added and

incubated for an additional 2 hours. Afterward, beads were washed extensively with the
homogenization buffer and immune complex was eluted in SDS-PAGE sample buffer.
Total immime complex samples and protein samples from total tissue homogenates
were separated by SDS-PAGE,transferred to nitrocellulose membrane and incubated

with the antibody against PKCa. After washing and incubating with secondary
antibody, immrmoreactive proteins were visualized Muth the ECL detection system.
Materials. Phenylephrine,PDBu,and PD098059 were obtained from Sigma

(St. Louis, MO).Phosphorylated MYPTl/Thr^®^ and MYPT1/Thr^^° antibodies and
caldesmon antibody were obtained from Upstate(Lake Placid, NY). Phosphorylated

ERK42/44,(Thr^''^/Tyr^®'') antibodies were from Cell Signaling Technology (Berverly,
MA).Phosphorylated CPI-17/Thr^^ antibody and PKCa antibody were from Santa Cruz
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Biotechnology(santa Cruz, CA). All electrophoretic and immunoblot reagents were from
Bio-Rad. General laboratory reagents were of analytical grade or better and were

purchased from Sigma and Fisher Scientific. All drugs were prepared fresh each day and
kept on ice throughout the experiment.
Data analysis. Data were analyzed using GraphPad Prism (GraphPad software;
San Diego, CA). Values are means ± SEM. Differences were evaluated for statistical
significance(P < 0.05) by two-way ANOVA and Student's t-test.
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Results

Phenylephrine-induced contractions andphosphorylation ofERK,MYPTl,and

CPI-17. Fig. 1 shows temporal relationships between phenylephrine-induced

contractions and phosphorylation ofERK,MYPTl/Thr^^° and CPI-17/Thr^^, measured
simultaneously in the same tissues of pregnant uterine arteries. Phenylephrine produced

time-dependent and concurrent increases in phosphorylation ofERK and MYPTl/Thr®^"

that preceded the contractions. Phenylephrine-induced phosphorylation of CPI-17/Thr^^
trailed phosphorylations ofERK and MYPTl/Thr®^®, but was concurrent with the
contractions.

Effect ofPD098059 on phenylephrine-induced phosphorylation ofERK44/42.
Our previous studies(55)have demonstrated that PKC activation stimulates a time-

dependent increase in ERK44/42 phosphorylation in the pregnant uterine artery, which is
blocked by PD098059,the MEK/ERK inhibitor. As shown in Fig. 2, phenylephrineinduced time-dependent increases in phosphorylation of both ERK44 and ERK42 were
also blocked by PD098059.

Effect ofPD098059 on phenylephrine-induced phosphorylation of

MYPTl/Thr^^'^ and MYPTl/Thr^^^. Previous studies suggested a differential regulation
of phosphorylation of MYPTl/Thr^^" and MYPTl/Thr®^^ in smooth muscle. Agonists
stimulated phosphorylation of MYPTl/Thr^^" but not MYPTl/Thr^^^(46). Basal

phosphorylation levels of MYPTl/Thr^^^ were detected in the uterine artery (Fig. 3).
Consistent with previous studies, phenylephrine did not increase MYPT/Thr®^^
phosphorylation in the uterine artery (Fig. 3). This was not altered by inhibition ofERK
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with PD098059. In contrast, phenylephrine induced a time-dependent increase in

phosphorylation of MYPTl/Thr^^", which was blocked in the presence ofPD098059
(Fig. 4).

Effect ofPD098059 on phenylephrine-inducedphosphorylation ofCPI-

17/Thi^^. Phenylephrine produced a time-dependent increase in phosphorylation of CPI17 in the pregnant uterine artery (Fig. 5). PD098059 showed a tendency to decrease
phenylephrine-induced CPI-17 phosphorylation, which did not reach a statistically
significant level(Fig. 5).
PDBu-induced contraction and phosphorylation ofCPI-17. Given that CPI-

17 is a PKC substrate and phosphorylated CPI-17 plays an important role in the
0-i-

regulation of Ca sensitivity of myofilaments, we determined the temporal relationship

between PDBu-induced phosphorylation of CPI-I7/Thr^^ and contractions measured
simultaneously in the same tissues. As shown in figure 6,PDBu produced a time-

dependent increase in phosphorylation of CPI-17/Thf^^ that preceded the contractions.
PDBu-induced translocation ofPKCa isozyme. We have previously

demonstrated that PDBu increases particulate-to-cytosolic PKC activity ratio in the
uterine artery, which is blocked by staurosporine (56). To determine the isozyme
involved in PDBu-stimulated PKC activity, we determined the effect ofPDBu on the

distributiontifPKCa in cytosolic and particulate fractions. The tissues were pretreated
with 0.1 pM staurosporine for 30 min before the addition ofPDBu(3 pM for 30 min).
PKCa levels in the cytosolic and particulate fractions were determined by Western
blotting using the PKCa antibody. Fig. 7 shows that PDBu significantly increased
particulate-to-cytosolic PKCa ratio in the uterine artery, which was blocked by
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staurosporine. To confirm the translocation ofPKCa was from cytosol to cell plasma
membrane, we examined the immimohistochemical staining ofPKCa in freshly
isolated smooth muscle from the uterine artery. As shown in Fig. 8, in the resting cells,
PKCa was distributed in the cytosol. PDBu induced a translocation ofPKCa from

cytosol to plasma membrane, which was accompanied by contractions of the cells.
Co-immunoprecipitation ofPKCa and caldesmon. Our recent studies have
suggested that PKC may directly phosphorylate caldesmon in the uterine artery (55).

The direct interaction ofPKCa and caldesmon was determined by coimmimoprecipitation ofPKCa and caldesmon. As shown in Fig. 9,PKCa was detected
in the caldesmon iminunoprecipitates in PDBu-stimulated tissues, but not in the control,
suggesting a direct interaction between the activated PKCa with caldesmon in the uterine
artery.
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Discussion

The main findings ofthe present study are as follows: 1) phenylephrine induces

phosphorylation ofERK and MYPTl/Thr^'" that precedes the contractions, 2)

phenylephrine-induced phosphorylation of MYPTl/Thr^^^ is mediated in part by
activation ofERK,3)phenylephrine produces concurrent phosphorylation of CPI-

17/Thr^^ and contractions, and the phosphorylation of CPI-17/Thr^® is not mediated by
ERK activation,4)phenylephrine does not increase phosphorylation of MYPTl/Thr^^^,
no

5)PDBu activates PKCa isozyme and induces a time-dependent increase in CPI-17/Thr
phosphorylation that precedes the contractions, 6)activated PKCa coimmunoprecipitates with the actin-binding protein caldesmon, in the uterine artery.
It has been demonstrated in many studies that different agents, which produce
smooth muscle contraction, activate ERK at the same time (2, 5,11,12, 53). Recently,
we have shown that the MEK/ERK inhibitor PD098059 selectively inhibits

phenylephrine-induced contractions in the pregnant, but not in nonpregnant, uterine
arteries, suggesting that pregnancy enhances the role ofERK in ai-adrenoceptormediated contractions in the uterine artery(56). In the present study, we found that
phenylephrine produced a time-dependent increase in phosphorylation of both ERK44 and

ERK42, which was inhibited by PD098059. This supports a role ERK in the regulation of
ai-adrenoceptor-mediated contractions in the uterine artery. Different signaling
transduction mechanisms have been reported in the ERK-mediated regulation ofsmooth
muscle contraction. Previous studies have shown that PD098059 does not affect agonist"A

induced [Ca^^i in isolated smooth muscle cells but inhibits agonist-induced smooth
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muscle contraction by decreasing Ca^"^ sensitivity of contractile proteins(1, 2, 5,12,17).
Our previous studies have also demonstrated that inhibition ofERK by PD098059

significantly decreases the Ca^"^ sensitivity of MLC2ophosphorylation in response to

phenylephrine, i.e., less MLC20phosphorylation at a given intracellular Ca^^
concentration in the uterine artery(55). It has been proposed that ERK mediates smooth
muscle contraction through the thin filament regulatory pathway by phosphorylation of
caldesmon(2,17, 34). However, our recent studies have demonstrated that in the
780

pregnant uterine artery phosphorylation of ERK-specific site Ser

of caldesmon may not

lead to the reversal of caldesmon inhibitory effect on myosin ATPase. Instead,
780

phosphorylation of caldesmon/Ser

may stabilize its inhibitory effect on actin-activated

myosin ATPase (55).
In the present study, we have demonstrated that phosphorylation of

MYPT1/Thr^^° precedes phenylephrine-mediated contractions. The finding that
MYPTl/Thr^^"consisted oftwo bands in the present study is in agreement with
previous findings. It has been shown that MYPTl in smooth muscle consists oftwo

isoforms and bands, but often the separation is not distinct(42, 54). The present finding

that the time course of MYPTl/Thr^^° phosphorylation resembled that of phenylephrineinduced MLC20 phosphorylation(55)and preceded contractions suggests that

phenylephrine-mediated Ca^"^ sensitization is peirtly regulated though phosphorylation

of MYPTI/Thr®^''resulting in an inhibition of MLCP activity in the uterine artery.

Although MYPTl/Thr^^® was originally shown not an inhibitory site in vitro (9), recent
study demonstrated that its phosphorylation state might affect localization of MLCP
and its catalytic subvmit on myosin (51). The present finding that PD098059 blocked
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both ERK and MYPTl/Thr®^" phosphorylation induced by phenylephrine suggests that
ERK-mediated regulation of Ca^"^ sensitivity of MLC20 phosphorylation is mediated in

part though MYPTl/Thr®^" phosphorylation in the uterine artery. It has been shown that
Rho-kinase(ROK)is activated in response to G-protein activation, and is responsible

for the phosphorylation of MYPTl/Thr^^® and inhibition of MLCP (9, 25, 26). ROK is
activated by the Ras-related monomeric GTPase, Rho, which increases force at constant

intracellular Ca^^ concentrations(14). However,the precise mechanism of ROK
activation that leads to phosphorylation of MYPTl in smooth muscle is not yet known.
There are concerns as to the access ofROK to its substrate MYPTl because both Rho

and ROK have to be recruited from a cytosolic pool to the cell membrane for activation
(10,49). The present finding suggests that ERK may be a link between activated ROK
/

and phosphorylation of MYPTl in the uterine artery. Consistent with the present

finding, previous studies demonstrated that RhoA was involved in the Angiotensin IIinduced ERK activation and contractions in intact fat mesenteric resistance arteries

(32). In addition, Krepinsky et al.(30) also reported that the early activation of RhoA
was essential for stretch-induced ERK activation in mesangial cells.

At least two phosphorylation sites of MYPTl have been identified at Thr^^^ and
Thr®^® (46). The present finding that phenylephrine did not increase phosphorylation of

MYPTl/Thr^^^ in the uterine artery is consistent with previous findings that
OCA

MYPTl/Thr

is phosphorylated by Rho-kinase through agonist activation, and

MYPTl/Thr^^® is constitutively phosphorylated, by kinases other than Rho-kinase, and
dose not respond to agonists(26, 37,46). These findings suggest an exciting hypothesis
that the different phosphorylation sites may regulate MLCP activities differently at
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basal and agonist-stimulated states. Basal levels of phosphorylated MYPTl/Thr^®^ have
been demonstrated in the uterine artery in the present study, yet the mechanisms

involved in the regulation of MYPTl/Thr^^^ in the uterine artery is not clear at present.
The finding that phenylephrine-induced phosphorylation of CPI-17 was
concurrent with the contractions suggests that phosphorylated CPI-17 may also be

important in phenylephrine-mediated Ca^^ sensitization of myofilaments. Previous
studies suggested that phosphorylated CPI-17/Thr^^ was a potent inhibitor of catalytic
subimit(PPlc)of MLCP (46). However,the finding that phenylephrine-induced CPI-17

phosphorylation trailed phenylephrine-induced MLC20 phosphorylation(55)suggests
^I

that it may not be important in the regulation of Ca sensitivity of MLC20
phosphorylation in the uterine artery. This is further supported by the results ofPKC-

mediated responses in the uterine artery. In the present study, we found that activation
ofPKC by PDBu induced phosphorylation of CPI-17 that preceded the contractions.
CPI-17 was initially recognized as a PKC substrate and phosphorylated by PKC (8).
However,interestingly, our previous studies have demonstrated that activation PKC

produces contractions without changes in MLC20 phosphorylation levels in the uterine
artery(55). These findings suggest that PKC-mediated phosphorylation of CPI-17 may
not contribute to regulation of MLCP activity and MLC20 phosphorylation in the uterine

artery. Woodsome et al.(54)reported that PDBu significantly increased both CPI-

17/Thr^^ phosphorylation and MLC20 phosphorylation in femoral artery, but increased
CPI-17/ Thr^^ phosphorylation without increase in MLC20 phosphorylation in vas
deferens smooth muscle. These studies suggest that the role of phosphorylated CPI-17 in

the regulation of MLCP activity and Ca sensitivity of MLC20 phosphorylation is tissue-
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specific. It is not clear whether or how phosphorylated CPI-17 regulates Ca^"^ sensitivity
in the uterine artery. In addition to the thick filament regulation through MLCP,Ca^^
sensitivity is also regulated by the smooth muscle actin-binding protein caldesmon that
inhibits myosin ATPase activity (34). Remove of caldesmon-mediated inhibition can be

achieved by phosphorylation of caldesmon and/or a binding of other regulatory

proteins, e.g. Ca^Vcalmodulin, which reverse its inhibitory effect on myosin ATPase.
Given that phosphorylated CPl-17 is a regulatory binding protein and binds to target

proteins, e.g. the catalytic subunit of MLCP,it is speculated that it may regulate Ca^"^
sensitivity in the uterine artery by binding to caldesmon and reversing its inhibitory effect
on myosin ATPase.

In the present study, we demonstrated that PDBu activated PKCa isozyme in

the uterine artery by stimulating its translocation from cytosol to cell plasma
membranes. This is consistent with our previous finding that PDBu increased

particulate-to-cytosolic PKC activity ratio in the uterine artery (56). PKCa has been
implicated in smooth muscle contractions, and is involved in the regulation of
myogenic tone of vascular smooth muscle (6, 57). Previous studies have demonstrated

that activation ofPKC may increase phosphorylation of caldesmon at sites other than
ERK-dependent phosphorylation sites(47, 50, 52). In sheep aorta, PKC phosphorylated

caldesmon both in native thin filaments and in the isolated state at multiple sites of Ser'^',

Ser^®^, Ser^"", Ser®^', Ser^^^ and Ser^^^, decreased caldesmon's inhibitory effect on myosin
ATPase (52). Our recent studies in pregnant ovine uterine arteries suggested that PKC

induced phosphorylation of caldesmon at Ser^^® indirectly through activation ofERK,as
well as at other site(s)through unknown mechanisms(55). It is the phosphorylation of
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7R0

caldesmon at site(s) other than Ser

that may be important in reversing the inhibitory

effect of caldesmon on myosin ATPase and leading to contractions. In the present study,
we demonstrated a co-immunoprecipitation of activated PKCa with caldesmon,
indicating a direct interaction between the activated PKCa with caldesmon in the uterine

artery. This provides a stipport for PKC-mediated direct phosphorylation of caldesmon in
the uterine artery.

In summary, we have demonstrated in pregnant ovine uterine arteries that ai-

adrenoceptor-mediated Ca^"^ sensitization of MLC20 phosphorylation is regulated in part
through the ERK-dependent phosphorylation of MYPT1/Thr^^°. ai-Adrenoceptor- and
PKC-mediated phosphorylation of CPI-17/Thr^^ may not be involved in the regulation of
MLCP activity and MLC20 phosphorylation. The potential role of phosphorylated CPI-

17/Thr in the regulation of Ca sensitivity through the thin filament regulation in the

uterine artery presents an intriguing avenue for future investigation. The present study
has also demonstrated a role ofPKCa isozyme in the PKC-mediated responses, and
suggested a role ofPKCa in a direct phosphorylation of caldesmon in the uterine artery.
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Figure 1. Time courses of phenylephrine-induced phosphorylation of ERK44,

MYPTl/Thr^^®, CPI-17/Thr^^ and contractions in the uterine artery. Uterine arterial
rings from pregnant sheep were stimulated with 3 pM phenylephrine. Contractile
responses were terminated at the various time points indicated, and phosphorylated levels

of ERK44, MYPTl/Thr^^''and CPI-17/Thr^^ were determined in the same tissue by
Western blotting. Data are means ± SEM oftissues from 4 animals.
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Figure 2. Effect of PD098059 on phenylephrine-induced phosphorylation of ERK
44/42 in the uterine artery. Uterine arterial rings from pregnant sheep were pretreated
with 30 pM PD098059 or the vehicle DMSO (control)for 30 min,followed by

stimulation with 3 pM phenylephrine. Representative Western immunoblots show

phosphorylated ERK44/42 induced by phenylephrine in the absence or presence of
PD098059 at 0-300 s. Data are means ± SEM oftissues from 6 animals. Two-way
ANOVA analysis indicates a significant difference between control and PD098059

treated samples(P < 0.05).
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Figure 3. Effect of PD098059 on phenylephrine-induced phosphorylation of

MYpTi/xhr®'® in the uterine artery. Uterine arterial rings from pregnant sheep were
pretreated with 30 pM PD098059 or the vehicle DMSO (control)for 30 min,followed by
stimulation with 3 pM phenylephrine. Representative Western immunoblots show

phosphorylated MYPTl/Thr®^^ induced by phenylephrine in the absence or presence of
PD098059 at 0-300 s. Data are means ± SEM oftissues from 3 animals.
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Figure 4. Effect of PD098059 on phenylephrine-induced phosphorylation of
•
•
MYPTl/Thr850 in
the uterine
artery. Uterine arterial rings from pregnant sheep were

pretreated with 30 pM PD098059 or the vehicle DMSO (control)for 30 min^ followed by
stimulation with 3 pM phenylephrine. Representative Western immunoblots show

phosphorylated MYPTl/Thr^^" induced by phenylephrine in the absence or presence of
PD098059 at 0-300 s. Data are means ± SEM oftissues from 6 animals. Two-way
ANOVA analysis indicates a significant difference between control and PD098059
treated samples(P < 0.05).
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Figure 5. Effect of PD098059 on phenylephrine-induced phosphorylation of CPIrri
38 •
•
17/Thr
in the uterine
artery. Uterine arterial rings from pregnant sheep were

pretreated with 30 pM PD098059 or the vehicle DMSO (control)for 30 min,followed by
stimulation with 3 pM phenylephrine. Representative Western immunoblots show

phosphorylated CPI-17/Thr^^ induced by phenylephrine in the absence or presence of
PD098059 at 0-300 s. Data are means ± SEM oftissues from 4 to 5 animals. Two-way
ANOVA analysis indicates no significant difference between control and PD098059
treated samples(P > 0.05).
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Figure 6. Time courses of PDBu-induced phosphorylation of CPI-17/Thr^^ and
contractions in the uterine artery. Uterine arterial rings from pregnant sheep were
stimulated with 5 pM PDBu. Contractile responses were terminated at the various time

points indicated, and phosphorylated levels of CPI-17/Thr^^ were determined in the same
tissue by Western blotting. Data are means ± SEM of tissues from 5 animals.
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Figure 7. PDBu-induced PKCa translocation in the uterine artery. Uterine arterial

rings from pregnant sheep were pretreated in the absence or presence of 0.1 pM
staurosporine (Stan)for 30 min,followed by stimulation with 3 pM PDBu for 30 min.
Representative Western immunoblots show PKCa determined by Western blotting in the
cytosol and membrane particulate fractions. Data are means ± SEM oftissues from 5
animals. * P < 0.05, v^. control.
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Figure 8. PDBu-induced redistribution ofPKCa in uterine artery smooth muscle
cells. Freshly isolated smooth muscle cells from pregnant uterine arteries were treated
with PDBu(5 pM)or vehicle control for 20 min. After fixation, cells were labeled with

anti-PKCa antibody as described in Methods. Representative fluoro-microscopy images
show the cells stained for PKCa(green) and nuclei (blue). At resting condition, uterine
artery smooth muscle cells showed typical elongated spindle shape, and a relatively
homogeneous cytosolic staining for PKCa.PDBu stimulated a translocation ofPKCa

from cytosol to the cell plasma membrane, which was accompanied with a shortening of
smooth muscle cells. The result was confirmed by three experiments.
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Figure 9. Co-immunoprecipitation ofPKCa and caldesmon in the uterine artery.
Uterine arterial rings from pregnant sheep were treated with 5 pM PDBu or the vehicle

(control)for 5 min. Immunoprecipitation of caldesmon was performed using the
caldesmon antibody. Immune complex were separated by SDS-PAGE,transferred to

nitrocellulose membrane, and blotted with the PKCa antibody. The representative
Western immunoblot shows that PKCa in the caldesmon immunoprecipitates was

detected in PDBu stimulated samples, but not in the control. The result was confirmed by
three experiments.
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CHAPTER SIX

Summary

Potential role of ERK in regulation of uterine artery contraction

It has been demonstrated in many studies that different agents that produce
contractions of smooth muscle, activate ERK at the same time (3, 7, 8,12, 14). However,

conflicting results were obtained regarding a role for ERK in smooth muscle contractile
regulation. The preceding serial studies have been an in-depth look at the potential role
ofERK in regulation of uterine artery contraction, the interactions among ai-adrenergic
receptor agonist,PKC and ERK,and their mediated changes in the down stream
signaling pathways during pregnancy.

In the studies of chapter two, we investigated the potential role ofERK in uterine
artery contraction, and tested the hypothesis that pregnancy up-regulated ERK-mediated
function in the uterine artery. Our report, for the first time, provides direct evidence that

ERK plays an important role in the regulation of uterine artery contractility, and its effect
is agonist-dependent. More importantly, pregnancy selectively enhances the role ofERK
in ai-adrenoceptor-mediated contractions and its effect in suppressing protein kinase C-

mediated contraction in the uterine artery. In addition, both the Ca^"^-dependent and
\

independent components are involved in the ERK pathway in the uterine artery. The lack

of effect ofPD-98059 on KCl-induced contractions in both nonpregnant and pregnant

uterine arteries suggests that the function of Ca^^ charmels may not be regulated by the
ERK pathway in uterine arteries. This is in agreement with several previous findings in
different animal models and arterial types(8,11, 24). Our finding that PD-98059
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inhibited 5-HT-induced contractions ofthe uterine artery is in agreement with the
previous study in which 5-HT-mediated contractions were inhibited by PD-98059 in rat
aorta, mesenteric artery, and tail artery (36). The results suggest the involvement ofthe

ERK pathway in 5-HT-induced contractions ofthe uterine artery. The finding that the

inhibitions ofPD-98059 on 5-HT-induced contractions were not different in pregnant and
nonpregnant Uterine arteries suggests that the effect ofERK on the 5-HT-mediated

contraction is not regulated by pregnancy. Unlike its effect on the 5-HT-mediated

contraction, PD-98059 showed no effect on the phenylephrine-induced contractions in

nonpregnant uterine artery. Nevertheless,PD-98059 did inhibit phenylephrine-mediated

contractions in pregnant uterine artery. These results suggest that pregnancy up-regulates
the coupling ofthe ERK pathway to ai-adrenoceptor-mediated contractions in the uterine
artery. Given that both 5-HT and ai-adrenoceptor-mediated contractions share a

common downstream signal, i.e. inositol 1,4,5-trisphosphate, in the uterine artery, it is
intriguing that PD-98059 differentially regulated 5-HT and phenylephrine-induced
contractions in uterine arteries. This would suggest a specific coupling ofthe ERK

pathway to individual receptor signaling pathways. The finding that the PDBu-induced

contraction was significantly attenuated in pregnant uterine artery is in agreement with
previous results in rat thoracic aorta(22), suggesting that the role ofPKC in the

regulation of uterine vascular tone is down-regulated during pregnancy. PD-98059 had
no effect on the PDBu-induced contraction in nonpregnant uterine arteries but

significantly increased PDBu-induced contractions in pregnant uterine arteries. To our
knowledge, it has not been reported previously that PD-98059 increases contractions to
any agonists examined. The finding that PD-98059 increased PDBu-induced
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contractions of pregnant uterine arteries and eliminated its difference between
nonpregnant and pregnant uterine arteries is likely to have physiological significance, and

suggests that ERK may play a very important role in increased uterine blood flow by
suppressing the PKC-mediated contraction during pregnancy. Consistent with this

notion, the present study demonstrated a significant increase in ERK-2 protein levels in
pregnant, as compared with nonpregnant, uterine arteries. This is in agreement with

recent findings in uterine artery endothelial cells in which pregnancy is associated with a
dramatic enhancement in ERK-2 signaling pathway (6,12).

ERK regulates uterine artery contraction through both thick and thin filament
regulatory pathways

In chapter three, we further explored the mechanisms ERK-mediated uterine

artery contraction. We found that ERK regulates contraction through both thick and thin
filament regulatory pathways in the uterine artery.

Our findings reported in chapter three, that phenylephrine-induced contraction

was initiated by an increase in [Ca^"^i and LC20 phosphorylation, and that PDBu-induced

contraction was not involved in changes of[Ca^^]i and LC20 phosphorylation, suggest
that both thick filament and thin filament regulation play an important role in regulation
of uterine arterial smooth muscle contractility. To address the possible role ofERK
involvernent in thick filament regulation ofthe uterine arterial smooth muscle

contraction, we examined the temporal relationships among isometric tension,[Ca^"^i and
LC20 phosphorylation-stimulated by PE after pretreatment ofERK inhibitor in the
uterine artery. We found that inhibition ofERK MAP kinase resulted in a decrease in
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LC20 phosphorylation, thus lead to reduce the contractile tension, suggesting a role for
ERK in thick filament regulation. Similar results were obtained in porcine carotid artery,
in which PD098059-mediated inhibition of endothelin-1-induced contraction was

associated with a redustion in LC20 phosphorylation (9).

Our data(chapter two)demonstrated clearly that PD098059-mediated inhibition

of phenylephrine-induced contraction was associated with a decrease in [Ca^"^]i and Ca^^
sensitivity in the uterine artery. This suggests that, in addition to the Ca^"^-independent
pathway as previously proposed (1,3,11),the ERK signaling pathway also involves the
^I

Ca -dependent components of vascular contractions. In addition, we found that

PD098059 significantly decreased Ca^^ sensitivity of LC20 phosphorylation in response to
phenylephrine, i.e. less LC20 phosphorylation at the given [Ca^^],in the presence of
PD098059. Because alterations in the activities of MLCK or MLCP at fixed [Ca^"^], will
^I

^

affect the Ca sensitivity of LC20 phosphorylation, the results suggest that, in addition to

the regulation of MLCK activity through changes in [Ca^^,,ERK may also regulate
either MLCK or/and MLCP activities independent of changes in [Ca^^];.
The notion that ERK may regulate thin filament regulatory pathways has been
supported by the results ofPKC-mediated contractions in the uterine artery. Our data

indicated that PDBu induced contractions independent ofchanges in either [Ca^"^, or LC20
phosphorylation levels. This suggests that PKC-induced contraction in the uterine artery is

mediated predominately through thin filament regulatory pathways. Moreover,our finding

that PD098059 enhanced PKC-mediated contraction without changing either [Ca^^], or
LC20 phosphorylation levels reenforces the conclusion that ERK inhibits the thin filament

regulatory pathway in the uterine artery.
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Taken together, these findings suggest that ERK may regulate force by a dual
regulation ofthick and thin filaments in uterine artery smooth muscle. ERK potentiates
the thick filament regulatory pathway by enhancing LC20 phosphorylation via increases

in [Ca^^]/ and Ca^"^ sensitivity of LC20 phosphorylation. In contrast, ERK attenuates the
thin filament regulatory pathway, and suppresses contractions independent of changes in
LC20 phosphorylation in the uterine artery.

ERK-dependent phosphorylation of caldesmon inhibits PKC-mediated contraction

In chapter three, we demonstrated that PDBu produced parallel time courses in

increasing phosphorylation ofERK42/44 and caldesmon(CaD)at Ser'^^ and the
phosphorylation was blocked by PD098059,suggesting ERK-mediated phosphorylation

of Ser'^^ in CaD in the uterine artery. This is in agreement with previous findings(10).
The novel finding ofthe present study is that PD098059 had opposite effects on PDBu-

induced CaD phosphorylation at Ser^^^ and contractions. It blocked phosphorylation of

CaD at Ser^^^, but potentiated the contractions. This suggests that ERK-dependent
phosphorylation of CaD at Ser'^^ may not be involved in the PDBu-induced contraction,
but rather inhibit it in the uterine artery.
CaD fimctions as a thin filament regulatory protein and exerts an inhibitory effect

on vascular smooth muscle contractions(13,23,34). It has been proposed that ERK-

mediated phosphorylation of CaD reverses the inhibitory activity ofCaD on actin-activated
myosin ATPase,hence activating the thin filament pathway(18,20,31). Nonetheless, the

importance of CaD phosphorylation at ERK specific sites (particularly at Ser^^^) in
smooth muscle contraction remains controversial(9,29, 35). From our findings in
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chapter three, we propose that in sheep uterine artery PKC induces phosphorylation of

CaD at Ser^^^ through activation ofERK,as well as at other site(s) through unknown
mechanisms. It is the phosphorylation of CaD at site(s) other than Ser'^^ that may be
important in reversing the inhibitory effect of CaD on myosin ATPase and leading to

contractions. Phosphorylation of ERK-dependent Ser^^^ may not lead to the reversal of

CaD inhibitory effects on myosin ATPase. Instead, phosphorylation of Ser^^^ may inhibit
PKC-mediated phosphorylation ofthe other site(s).

Role of ERK/PKC in the regulation of MYPTl and CPI-17 phosphorylation

It has demonstrated that the increase in force induced by agonist at a given [Ca^^i,
is due to the inhibition of myosin light chain phosphalase(MLCP). MLCP inhibition
leads to an increase in both myosin light chain phosphorylation and contractile force of

smooth muscle without any changes in Ca^^, hence causing an enhancement ofthe

contractile Ca^"^ sensitivity (25,26). We have previously demonstrated that ERK/PKC
signaling pathways play a key role in regulation of Ca^"^ sensitivity and contractility in
(

uterine artery. We speculate that ERK may regulate uterine artery contraction, at least,

partly through inhibition of MLCP activity. Inhibition of MLCP is regulated by at least
three mechanisms: a. phosphorylation of MYPTl, h. arachidonic acid-induced

dissociation of the holoenzyme, and c. PKC-mediated phosphorylation of CPI-17,

which becomes a potent inhibitor ofPPlc(a catalytic subimit of MLCP). At least two

phosphorylation sites of MYPTl have been identified at Thr^^^ and Thr^^°(34), which
are regulated through the RhoA/ROK pathway in a variety cells, including smooth
muscle (21).
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In chapter five, we have demonstrated that basal levels of phosphorylated

MYPTl/Thr^^^ had been detected, but the phosphorylation level was not increased in
response to ai-adrenoceptor activation in the uterine artery. This implies that there is no

ai-adrenoceptor mediated G-protein-coupled signaling pathway leading to Thr®^®
phosphorylation in the uterine artery smooth muscle. In contrast to Thr^'®,
or A

MYPTI/Thr

is significantly phosphorylated in response to activation of ai-

adrenoceptor in the uterine artery. These findings suggest an exciting hypothesis that
the different phosphorylation sites may regulate MLCP activities differently at basal

and agonist-stimulated states. Our finding that PD098058 inhibited phenylephrine-

induced MYPTl/Thr^^® phosphorylation suggests that ERK might involve the
phosphorylation of MYPTl/Thr^^® in the uterine artery. A previous report demonstrated
that Rho A was involved in the Ang Il-induced ERK activation and contraction in

intact rat mesenteric resistance arteries (30). Krepinsky et al.(28) also reported that the
early activation of RhoA is essential for stretch-induced actin stress fiber formation and

ERK activation in mesangial cells. These findings suggest that ROK is upstream of
ERK and imply that MEK/ERK might be a link between activated ROK and MYPTI

and may be responsible for ai-adrenoceptor-mediated Ca^"^ sensitization in the uterine
artery contraction.

CPI-17 was initially recognized as a PKC substrate and phosphorylated by PKC
(15), and also phosphoryalted by ROK kinase in vitro (27). Thus, both PKC and ROK

signaling pathways may contribute to regulation of MLCP activity through increase in
CPI-17 phosphorylation. Our results are consistent with earlier other reports that
activation of ai-adrenoceptor and PKC result in an increase of CPI-17 phosphoryaltion at
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Thr^^ in the uterine artery. However,interestingly, our previous study(Chapter three) has
demonstrated that PKC produces contraction without significantly increase in myosin
light chain phosphorylation levels in the uterine artery. This clearly suggests that PKCCPI-17 pathway might not contribute to regulation of MLCP activity and LC20

phosphorylation in the uterine artery. We speculate that phosphorylated CPI-17 may

facilitate or localize PKC binding to caldesmon and regulate Ca^"^ sensitivity of
contractions through the thin filament pathway.

Pregnancy differentially regulates thick and thin filament regulatory pathway
We have demonstrated (chapter three) in the pregnant uterine artery that aiadrenoceptor-mediated contraction is regulated through thick and thin filament pathways,
with the thick filament regulatory pathway predominating. However,PKC-mediated

contraction is regulated predominantly through thin filament pathways. Little is known
about the adaptation of contractile mechanisms of uterine artery smooth muscle to
pregnancy. We speculate that pregnancy differentially regulates thick and thin filament
regulatory pathways in uterine artery.

In chapter four, we have demonstrated that ai-adrenoceptor-mediated
contractions are increased by pregnancy, which is in agreement with previous studies(4,

5). This is probably due in part to a transient and reversible sympathetic denervation of

the uterine artery during pregnancy(32, 33), resulting in a sensitization of postsynaptic
ai-adrenoceptor-mediated responses. It is likely that multiple mechanisms are

contributed to this increase of ai-adrenoceptor-mediated contractions. Previous studies
demonstrated that the density of ai-adrenoceptors and norepinephrine binding affinity to
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tti-adrenoceptors are significantly increased in pregnant uterine artery (38). Further
more,the present finding that pregnancy significantly increased phenylephrine-induced
^I

[Ca ]i and LC20 phosphorylation suggests that pregnancy upregulates ai-adrenoceptormediated thick filament regulatory pathway.

The present study demonstrated that pregnancy decreased force development at
given levels of LC20 phosphorylation. This suggests that pregnancy mediated contraction

is also regulated, in addition to the thick filament pathway, by thin filament pathways in
the uterine artery smooth muscle cells. The finding that pregnancy potentiated aiadrenoceptor-mediated contraction in the uterine artery suggests that the thick filament

regulatory pathway, i.e., LC20 phosphorylation, predominates in ai-adrenoceptor-

mediated contractions. The idea that pregnancy may inhibit thin filament regulatory
pathways is fixrther supported by the results ofPKC-mediated contractions in the uterine
artery. In the present study, we have demonstrated that PKC-induced contractions are

independent ofchanges in MLC20 phosphorylation in both nonpregnant and pregnant
uterine arteries, indicating that in the uterine artery PKC-induced contractions were

mediated predominately through thin filament regulatory pathways. The finding that PKCmediated contractions were attenuated in the pregnant uterine artery in the present study
further suggests an adaptation ofthe thin filament regulatory pathway to pregnancy.

Conclusion and implications

Progressively increasing uterine blood flow is essential for fetal growth and
maturation. Uterine blood flow during pregnancy is controlled by two distinct
phenomena: phasic contractility and tone. Phasic contractility, which mediates short-
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term contractions, functions through catecholamine activation of ai-adrenergic receptors,
leading to generate inositol triphosphate (IP3) and Diacylglycerol(DAG). The phasic
contractions proceed as IP3 stimulates the release of intracellular calciiun stores that

activate the calmodulin-MLCK pathway,increasing LC20 phsophorylation and causing

myosin filaments to slide past actin filaments (i. e., activating thick filament pathway);

however,the resulting contraction is phasic, because the myosin is rapidly
dephosphorylated by phosphatases, and the free cytosolic calcium is quickly reduced. A
tonic contraction is initiated when the DAG generated during PIP2 hydrolysis binds to
and activates protein kinase C. The activated PKC then initiates a sustained contraction

through phosphophorylation ofthe actin-associated binding proteins and leading to
shortening ofthe actin filments (i. e., activating thin filament pathway).
During pregnancy, arterial contractility is a transient reduction in luminal

diameter in response to nerve stimulation or to an ai-adrenergic agonist, leading to shortterm reduction in uterine blood flow. However, at the same time, arterial tone is

progressively decreasing (i.e., increasing diameter) during pregnancy. It has reported that
progesterone is the only sex steroid that directly modulates the ai-AR/calmodulin-MLCK

pathway in the uterine artery (17). Progesterone of endogenous or exogenous origin
increases ai-AR numbers on uterine arterial smooth muscle membranes. This is

consisten with the high and maintained phasic contractility ofthe uterine arterial bed

throughout gestation(19). It retains its ability to phasically contract to shunt blood away
from the uterus to other vascular beds during times of acute maternal stress to facilitate
maternal survival. On the other hand,the progressive decrease in uterine arterial tone

during pregnancy seems to result from the metabolism of placental estrogens to
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vasoactive catechol forms(16). Catechol estrogens directly inhibit calcium uptake
through potential sensitive calcium channel, resulting in a reduced activity of membranebormd PKC-DAG complexes. Any factor that inhibits the PKC pathway would be
expected to decrease uterine arterial tone, resulting in increased vessel diameter and

blood flow. The goal of our research was to determine the mechanism(s) during
pregnancy that allow for progressive uterine arterial dilation and yet allow for brief

periods of constriction to facilitate maternal survival. Understanding these mechainisms
should allow development oftherapies to facilitate fetal growth and survival as well as

correct abnormalities ofthe uterine arterial vasulature resulting from diseas of toxicity.
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